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Hepatitis C virus (HCV) infection is one of the main causes of
chronic liver disease worldwide. The long-term impact of HCV
infection is highly variable, from minimal changes to extensive
ﬁbrosis and cirrhosis with or without hepatocellular carcinoma
(HCC). The number of chronically infected persons worldwide is
estimated to be about 160 million, but most of them are unaware
of their infection. The implementation of extended criteria for
screening of HCV, such as targeting birth cohorts, is the subject
of major debate among different stakeholders. Clinical care for
patients with HCV-related liver disease has advanced consider-
ably during the last two decades, thanks to an enhanced under-
standing of the pathophysiology of the disease, and because of
developments in diagnostic procedures and improvements in
therapy and prevention.
These EASL Clinical Practice Guidelines (CPGs) are intended to
assist physicians and other healthcare providers, as well as
patients and other interested individuals, in the clinical deci-
sion-making process by describing the optimal management of
patients with acute and chronic HCV infections. These guidelines
apply to therapies that are approved at the time of their publica-
tion. Two protease inhibitors (PIs) have completed phase III
development for patients infected with HCV genotype 1, and
are currently registered for use in Europe and elsewhere. There-
fore, these EASL CPGs on the management of HCV infection have
been updated to include guidance on the use of these two drugs,
and will be updated regularly based on approval of additionalJournal of Hepatology 20
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Open access under CC BY-NC-ND license.new therapies and clinical experience with them. Also, substance
users are increasingly considered as a treatable patient group at
risk. The EASL CPGs have been updated in this respect. The pre-
ceding HCV CPGs were published as recently as 2011 [1]. These
updated CPGs have built upon the earlier published work, so
much remains unchanged. In particular, dual therapy remains
the standard of care for patients with genotype non-1, and for
some patients with genotype 1 infection. The authors of the cur-
rent CPGs acknowledge the work undertaken by Professor Craxi
and the authors of the 2011 CPGs which forms the basis of the
current revision.Context
Epidemiology
It is estimated that approximately 160 million individuals, i.e.
2.35% of the world population, are chronically infected with
HCV [2]. Current estimates are that between 7.3 and 8.8 million
persons are infected with HCV in the European Union, i.e. twice
as many as an estimate made in 1997 [3]. Overall, HCV prevalence
across Europe ranges between 0.4% and 3.5%, with wide geograph-
ical variation and higher rates in the south and the east [4–6].
HCV is a positive strand RNA virus, characterized by high
sequence heterogeneity. Seven HCV genotypes, numbered 1 to
7, and a large number of subtypes have been described [6]. Geno-
types and subtypes (which are identiﬁed by lowercase letters),
differ among themselves by about 30% and 20% of their
sequences, respectively. Genotype 1 is the most prevalent geno-
type worldwide, with a higher proportion of subtype 1b in Eur-
ope and 1a in the USA. Genotype 3a is highly prevalent in the
European population of people who inject drugs (PWID). This
group is currently experiencing an increasing incidence and prev-
alence of infections with HCV genotype 4. Genotype 2 is found in
clusters in the Mediterranean region, while 5 and 6 are rare in
Europe [7]. The novel genotype 7 was identiﬁed in patients from
Canada and Belgium, possibly infected in Central Africa [8]. The
identiﬁcation of HCV genotypes and subtypes is not only of epi-
demiological interest, but it determines the type and duration
of antiviral therapy, including the risk of selecting resistance-
associated variants during therapy.
Up to the 1990’s, the principal routes of HCV infection were
blood transfusion, unsafe injection procedures, and intravenous
drug use (IDU). Taken together, these routes are estimated to
be responsible for approximately 70% of chronic cases in devel-
oped countries. Currently, however, screening of blood products14 vol. 60 j 392–420
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for HCV by means of enzyme immunoassays (EIA) and nucleic
acid testing has virtually eradicated transfusion-associated hepa-
titis C. Similarly, in the developed world, new HCV infections are
infrequently related to unsafe medical or surgical procedures.
Spread among the PWID community – facilitated by sharing par-
aphernalia, unstable housing, frequent cocaine use, and history of
imprisonment – now accounts for the vast majority of incident
cases in developed countries. High coverage of combined harm
reduction programs (e.g. opiate substitution treatment and nee-
dle exchange programs) may reduce HCV incidence in the PWID
community, and some modelling studies suggest that implemen-
tation of HCV treatment may even reduce transmission within
this population [9]. Other invasive behaviours, such as tattooing
or acupuncture with unsafe materials, are also implicated in
occasional HCV transmissions. The risk of perinatal and of heter-
osexual transmission of HCV is low, while male homosexual
activity has become an important transmission route in Western
countries [10]. On the other hand, the situation is quite different
in resource-poor countries, where lack of public awareness and
continuous use of unsafe medical tools still account for a consid-
erable proportion of new HCV infections.
Natural history and public health burden
Acute hepatitis C is rarely severe, and symptoms occur in 10 to
50% of cases. In Europe, HCV infection is responsible for about
10% of cases of acute hepatitis [11]. The incidence of acute HCV
infection has decreased and is now about 1/100,000 per year,
but this ﬁgure is probably an underestimate because it mainly
refers to symptomatic patients. Progression to persistent or
chronic infection occurs in about three quarters of cases, is inﬂu-
enced by the IL28B genotype, and is associated with chronic hep-
atitis of a variable degree and with variable rates of ﬁbrosis
progression. Only exceptionally does infection clear spontane-
ously in the chronic stage. Chronic hepatitis C proceeds towards
cirrhosis over several decades. On average, 10 to 20% of patients
develop cirrhosis over 20–30 years of infection [12]. In a meta-
analysis of cross-sectional studies of HCV-infected PWID, the
20-year cirrhosis prevalence was 15% [13]. Once at the cirrhotic
stage, the risk of developing HCC is approximately 1 to 5% per
year. Patients diagnosed with HCC have a 33% probability of
death during the ﬁrst year after diagnosis [14].
In Europe, and dependent on the relative proportion of
patients with hepatitis B virus (HBV) infection in the same geo-
graphical area, the prevalence of anti-HCV antibodies among
patients with cirrhosis ranges from 11 to 61% [15]. Similarly,
the prevalence of anti-HCV antibodies in patients with HCC
ranges from 18 to 64% [15]. Overall, the standardized mortality
rate in anti-HCV-positive persons ranges from 1.6 to 4.5, and
was as high as 25 in a recent study from Scotland [16]. It has been
estimated that, in countries where injecting drug use (IDU) is the
major risk factor for HCV infection, 20 to 25% of deaths among
HCV-infected individuals are from liver disease and 15 to 30%
are from drug-related causes, although the attributable risk of
death varies and is age-related [17].
In addition to the healthcare burden associated with HCV
monoinfection, Europe has a signiﬁcant population that is HCV/
HIV co-infected. Though they represent a small proportion of
all HCV-positives, they tend to have more advanced liver injury
and (to date) have exhibited disappointing response rates to anti-
viral therapy.Journal of Hepatology 201Hepatitis C progression to cirrhosis is highly variable, depend-
ing on the presence of cofactors capable of accelerating the ﬁbro-
tic process. Proven cofactors for ﬁbrosis progression include older
age at infection, male gender, chronic alcohol consumption, obes-
ity, insulin resistance and type 2 diabetes, and immunosuppres-
sion (such as that occurring after solid organ transplantation
and in untreated HIV infection). Importantly, despite slow HCV
disease progression over the initial 20 years of infection, advanc-
ing age may accelerate ﬁbrosis progression [18]. Tobacco smok-
ing may increase inﬂammation and accelerate ﬁbrosis [19].
Similarly, daily cannabis use has been associated with more
advanced liver ﬁbrosis, though recently published data have
questioned this association [20]. Coffee consumption is associ-
ated with lower inﬂammatory activity, less advanced ﬁbrosis
and reduced risk of developing HCC [21–23]. For all of the above
reasons, a mainstay of HCV management is the modiﬁcation of
cofactors. An additional consideration is the fact that many of
these cofactors also reduce the rate of response to interferon
(IFN)-based therapy.
The current standard of care and developing therapies
The primary goal of HCV therapy is to cure the infection, which is
generally associated with resolution of liver disease in patients
without cirrhosis. Patients with cirrhosis remain at risk of
life-threatening complications, albeit at a lower rate, even after
viral infection has been eradicated. The infection is cured in more
than 99% of patients who achieve a sustained virological response
(SVR), deﬁned as undetectable HCV RNA 24 weeks after treat-
ment completion. Until 2011, the combination of pegylated inter-
feron-a (pegylated IFN-a) and ribavirin (subsequently referred to
as PegIFN/RBV) was the approved treatment for chronic hepatitis
C [24]. With this regimen, patients infected with HCV genotype 1
had SVR rates of approximately 40% in North America and 50% in
Western Europe. Higher SVR rates were achieved in patients
infected with HCV genotypes 2, 3, 5, and 6 (up to about 80%,
and better for genotype 2 than for genotypes 3, 5, and 6) and
intermediate SVR rates were achieved in those with HCV
genotype 4 [7]. In 2011, telaprevir (TVR) and boceprevir (BOC)
were licensed for use in HCV genotype 1 infection. These two
drugs are ﬁrst-generation direct-acting antivirals (DAAs), both
targeting the HCV NS3/4A serine protease and thus referred to
as protease inhibitors (PIs), i.e. both TVR and BOC must be admin-
istered in combination with PegIFN/RBV. These triple therapy
regimens have proven effective for treatment-naïve and for
treatment-experienced patients, including previous null respond-
ers to dual PegIFN/RBV therapy. Indications for therapy, dosages,
schedules, side effects, and precautions are detailed in the sec-
tions below.
There are other DAAs at different stages of clinical develop-
ment, some of them targeting HCV genotype 1 as well as other
genotypes. Investigational drugs include second generation
NS3/4A serine protease inhibitors, nucleoside/nucleotide and
non-nucleoside inhibitors of the HCV RNA-dependent RNA poly-
merase, and NS5A inhibitors. Additionally, host-targeting antivi-
ral drugs (HTAs), such as cyclophilin inhibitors, target host cell
functions which are involved in the HCV life cycle. New therapeu-
tic strategies aim towards higher efﬁcacy, pan-genotypic activity,
shortened treatment duration, easier administration and
improved tolerability and patient adherence [25]. It is highly
likely that IFN-sparing and IFN-free regimens with or without4 vol. 60 j 392–420 393
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ribavirin, which are being evaluated in clinical trials, will enter
clinical practice in the next few years. Decisions about the need
for and timing of antiviral treatment will need to take into
account this rapid rate of change.Methodology
These EASL CPGs have been developed by a panel of experts cho-
sen by the EASL Governing Board. The recommendations were
peer-reviewed by external expert reviewers and approved by
the EASL Governing Board. The CPGs were established using data
collected from PubMed and Cochrane database searches. The
CPGs have been based as far as possible on evidence from existing
publications, and, if evidence was unavailable, the experts’
personal experiences and opinion. Where possible, the level of
evidence and recommendation are cited. The evidence and rec-
ommendations in these guidelines have been graded according
to the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system. The strength of recommenda-
tions thus reﬂects the quality of underlying evidence. The princi-
ples of the GRADE system have been enunciated [26]. The quality
of the evidence in the CPG has been classiﬁed into one of three
levels: high (A), moderate (B) or low (C). The GRADE system
offers two grades of recommendation: strong (1) or weak (2)
(Table 1). The CPGs thus consider the quality of evidence: the
higher the quality of evidence, the more likely a strong recom-
mendation is warranted; the greater the variability in values
and preferences, or the greater the uncertainty, the more likely
a weaker recommendation is warranted.
The HCV CPG Panel has considered the following questions:
- How should acute and chronic hepatitis C be diagnosed?
- What are the goals and endpoints of treatment?
- What are the results of current therapies and the predictors of
response?
- How should patients be assessed before therapy?
- What are the contra-indications to therapy?
- Who should be treated with current licensed drugs?
- For whom can treatment be deferred?
- What ﬁrst-line treatment should be prescribed?
- How should treatment be managed?
- How should treatment be tailored to the virological response?
- How can SVR rates of antiviral treatment be improved?
- How should patients with SVR be followed?
- What should be offered to those who fail to achieve SVR?
- How should patients with severe liver disease be treated?
- How should special groups of patients be treated?
- How should patients, infected after substance use, be treated?
- How should we treat patients with acute hepatitis C?
- How should untreated patients and non-sustained responders
be followed?
- What are the perspectives of new treatments?Guidelines
Diagnosis of acute and chronic hepatitis C
The diagnosis of acute and chronic HCV infection is based on the
detection of HCV RNA by a sensitive molecular method (lower
limit of detection <15 international units [IU]/ml). Anti-HCV394 Journal of Hepatology 201antibodies are detectable by enzyme immunoassay (EIA) in the
vast majority of patients with HCV infection but EIA results
may be negative in early acute hepatitis C and in profoundly
immunosuppressed patients. Following spontaneous or treat-
ment-induced viral clearance anti-HCV antibodies persist in the
absence of HCV RNA but may decline and ﬁnally disappear in
some individuals [27,28].
The diagnosis of acute hepatitis C can be conﬁdently made
only if seroconversion to anti-HCV antibodies can be docu-
mented, since there is no serological marker, which proves that
HCV infection is in the acute phase. About 50% of patients with
acute hepatitis C will be anti-HCV positive at diagnosis. In these
cases, acute hepatitis C can be suspected if the clinical signs
and symptoms are compatible with acute hepatitis C (alanine
aminotransferase [ALT] >10 the upper limit of normal, jaundice)
in the absence of a history of chronic liver disease or other causes
of acute hepatitis, and/or if a likely recent source of transmission
is identiﬁable. In all cases HCV RNA can be detected during the
acute phase although brief periods of undetectable HCV RNA
may occur.
The diagnosis of chronic hepatitis C is based on the detection
of both HCV antibodies and HCV RNA in the presence of signs of
chronic hepatitis, either by elevated aminotransferases or by his-
tology. Since, in the case of a newly acquired HCV infection, spon-
taneous viral clearance is very rare beyond four to six months of
infection, the diagnosis of chronic hepatitis C can be made after
that time period.
Recommendations
• Anti-HCV antibodies are the first line diagnostic test for
HCV infection 
(recommendation A1)
• In the case of suspected acute hepatitis C or in 
immunocompromised patients, HCV RNA testing should
be part of the initial evaluation 
(recommendation A1)
• If anti-HCV antibodies are detected, HCV RNA should
be determined by a sensitive molecular method 
(recommendation A1)
• Anti-HCV positive, HCV RNA negative individuals 
should be retested for HCV RNA 3 months later to
confirm a recovered infection 
(recommendation A1)Goals and endpoints of HCV therapy
The goal of therapy is to eradicate HCV infection in order to pre-
vent the complications of HCV-related liver and extrahepatic dis-
eases, including liver necroinﬂammation, ﬁbrosis, cirrhosis, HCC,
and death.
The endpoint of therapy is the SVR, deﬁned by undetectable
HCV RNA 24 weeks after the end of therapy, as assessed by a sen-
sitive molecular method with a lower limit of detection <15 IU/
ml (SVR24). Long-term follow-up studies have shown that an
SVR corresponds to a deﬁnitive cure of HCV infection in more
than 99% of cases [29]. The validity of using undetectable HCV4 vol. 60 j 392–420
Table 1. Evidence grading used in the EASL HCV Clinical Practice Guidelines (adapted from the GRADE system).
Evidence quality Notes Grading
High A
Moderate
change the estimate
Further research is very unlikely to change our confidence in the estimate of effect
Further research is likely to have an important impact on our confidence in the estimate of effect and may
Further research is very likely to have an important impact on our confidence in the estimate of effect and
B
Low
is likely to change the estimate. Any change of estimate is uncertain
C
Recommendation Notes Grading
Strong
patient-important outcomes, and cost
Factors influencing the strenght of the recommendation included the quality of the evidence, presumed 1
Weak Variability in preferences and values, or more uncertainty. Recommendation is made with less certainty, 
higher cost or resource consumption
2
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accepted by regulators in the US and Europe, given that the con-
cordance with SVR24 is 99% [30]. This concordance needs to be
further validated in ongoing clinical trials.
Recommendations
• The goal of therapy is to eradicate HCV infection to
prevent liver cirrhosis, HCC, and death. The endpoint of
therapy is undetectable HCV RNA in a sensitive assay
(<15 IU/ml) 12 and 24 weeks after the end of treatment
(i.e. an SVR) 
(recommendation A1) 
• In patients with cirrhosis, HCV eradication reduces the rate
of decompensation and will reduce, albeit not abolish, the
risk of HCC. In these patients screening for HCC should
be continued 
(recommendation A1) Pretherapeutic assessment
The causal relationship between HCV infection and liver disease
must be established, liver disease severity must be assessed,
and baseline virological parameters that will be useful to tailor
therapy should be determined.
Search for other causes of liver disease
Other causes of chronic liver disease, or factors which are likely
to affect the natural history or progression of liver disease, should
be systematically investigated and all patients should be tested
for other hepatotropic viruses, particularly HBV. Alcohol
consumption should be assessed and quantiﬁed, and speciﬁc
counselling to stop any use of alcohol should be given. Possible
co-morbidities, including alcoholism, co-infection with HIV, auto-
immunity, genetic or metabolic liver diseases (for instance
genetic hemochromatosis, diabetes or obesity) and the possibility
of drug-induced hepatotoxicity should be assessed.
Assessment of liver disease severity
Assessment of liver disease severity is recommended prior to
therapy. Identifying patients with cirrhosis is of particular impor-
tance, as the likelihood of response to therapy and post-treat-
ment prognosis are proportional to the stage of ﬁbrosis. The
absence of signiﬁcant ﬁbrosis may also have important implica-Journal of Hepatology 201tions for the choice or timing of therapy. Assessment of the stage
of ﬁbrosis by biopsy is not required in patients with clinical evi-
dence of cirrhosis. Patients with likely cirrhosis need screening
for HCC. Since signiﬁcant ﬁbrosis may be present in patients with
repeatedly normal ALT, evaluation of disease severity should be
performed regardless of ALT patterns.
Liver biopsy remains the reference method. The risk of severe
complications is very low (1/4,000 to 1/10,000). Based on the
abundant literature, in chronic hepatitis C alternative, non-inva-
sive methods can now be used instead of liver biopsy to assess
liver disease severity prior to therapy at a safe level of predict-
ability. Liver stiffness measurement (LSM) can be used to assess
liver ﬁbrosis in patients with chronic hepatitis C, provided that
consideration is given to factors that may adversely affect its per-
formance such as obesity. Well established panels of biomarkers
of ﬁbrosis can also be applied. Both LSM and biomarkers perform
well in the identiﬁcation of cirrhosis or no ﬁbrosis but they per-
form less well in resolving intermediate degrees of ﬁbrosis.
The combination of blood biomarkers or the combination of
LSM and a blood test improve accuracy and reduce the need for
liver biopsy to resolve uncertainty [31,32]. These tests are of
particular interest in patients with clotting disorders, though
transjugular liver biopsy may also be used safely in this situation
with the bonus that portal pressure can also be assessed. In case
of contradictory results with non-invasive markers, liver biopsy
may be indicated. Also, histology may be required in cases of
known or suspected mixed etiologies (e.g. HCV infection with
HBV infection, metabolic syndrome, alcoholism or autoimmunity).
HCV titre and genotype determination
HCV quantiﬁcation is indicated for the patient who may undergo
antiviral treatment. HCV quantiﬁcation should be made by a reli-
able sensitive assay, and levels should be expressed in IU/ml. The
HCV genotype should also be assessed prior to treatment initia-
tion. As the current therapy for genotype 1-infected patients
includes ﬁrst-generation PIs, subtyping is also relevant. Genotype
1a/b subtyping provides relevant information with respect to dif-
ferent response rates and genetic barriers to resistance to PIs
when used as components of triple therapy for genotype 1 infec-
tion [33]. For instance, emerging trial data show that subtype 1a
may be less susceptible than subtype 1b to treatment with some
DAA drug combinations.
Determination of host genetics
IL28B genotyping may provide useful information for making
clinical decisions in selected patients with genotypes 1 or 4.
The negative predictive value of an unfavourable IL28B genotype4 vol. 60 j 392–420 395
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is not sufﬁcient to be considered a futility rule. A favourable IL28B
genotype (IL28B CC) identiﬁes patients who are more likely to
achieve a rapid virological response (RVR) and who have a signif-
icant chance of cure with dual therapy [34,35]. In selected cases
with genotype 1, it may assist the physician and patient in man-
agement decisions.
Recommendations
• The causal relationship between HCV infection and liver
disease should be established 
(recommendation A1)
• The contribution of co-morbid conditions to the 
progression of liver disease must be evaluated 
and appropriate corrective measures implemented
(recommendation A1)
• Liver disease severity should be assessed prior to
therapy. Identifying patients with cirrhosis is of particular
importance, as their prognosis, their likelihood of 
response and the duration of therapy are altered 
(recommendation A1)
• Fibrosis stage can be assessed by non-invasive 
methods initially, with liver biopsy reserved for cases
where there is uncertainty or potential additional 
etiologies 
(recommendation B1)
• HCV RNA detection and quantification should be made
by a sensitive assay 
(lower limit of detection of <15 IU/ml) 
(recommendation A1)
 
• The HCV genotype must be assessed prior to 
treatment initiation and will determine the choice of
therapy, the dose of ribavirin and treatment duration
(recommendation A1)
• Subtyping of genotype 1a/1b may be relevant to PI-
based triple therapy 
(recommendation B2)
• IL28B genotyping is not a prerequisite for treating 
hepatitis C 
(recommendation B2)Contra-indications to therapy
IFN-a and ribavirin
Treatment of chronic hepatitis C with PegIFN/RBV-containing
regimens is absolutely contra-indicated in the following patient
groups: uncontrolled depression, psychosis or epilepsy; pregnant
women or couples unwilling to comply with adequate contracep-
tion; severe concurrent medical diseases; decompensated liver
disease (though treatment of patients with advanced liver dis-
ease whose parameters exceed label recommendations may be
feasible in experienced centres under careful monitoring).396 Journal of Hepatology 201Telaprevir or boceprevir based triple therapy
Generally, the same contra-indications apply to TVR- or BOC-
based triple therapy as to dual therapy with PegIFN/RBV (‘IFN-a
and ribavirin’, above). In patients with compensated cirrhosis,
treatment should be performed with special care as the incidence
of side effects (especially hematological disorders and severe
infections) is signiﬁcantly increased in triple vs. dual PegIFN/
RBV therapy, especially when serum albumin is <3.5 g/dl or
platelets <100,000 before starting treatment [36].Indications for treatment: Who should be treated?
All treatment-naïve patients with compensated chronic liver dis-
ease related to HCV, who are willing to be treated and who have
no contraindications to treatment, should be considered for ther-
apy. Treatment should be scheduled, rather than deferred, in
patients with advanced ﬁbrosis (METAVIR score F3 to F4) and
in those patients with clinically signiﬁcant extrahepatic manifes-
tations (symptomatic cryoglobulinemia or HCV immune com-
plexes nephropathy). For patients with minimal or no ﬁbrosis,
the timing of therapy is debatable, and treatment may be
deferred pending the development and availability of new thera-
pies. The decision to defer treatment for a speciﬁc patient should
also consider the patient’s preference and priorities, the natural
history and risk of progression, the presence of co-morbidities
and the patient’s age. Patients who have treatment deferred
should be assessed on a regular basis for evidence of progression,
to reconsider the indication for treatment, and to discuss new
therapies as they emerge.
Patients infected with HCV genotype 1 who failed to eradicate
HCV on prior therapy with PegIFN/RBV or with combination non-
pegylated IFN-a and ribavirin should be considered for treatment
with PI-based triple therapy. In this setting, triple therapy yields
SVR rates of 29 to 88%, depending on the type of previous non-
response and on the stage of liver disease. Re-treatment with
PegIFN/RBV, without the addition of a PI, is associated with low
SVR rates.
Patients with HCV genotypes other than 1 who have failed
previous IFN-a-based treatment can be considered for treatment
with PegIFN/RBV depending on careful assessment of factors such
as adequacy of prior treatment and stage of liver disease. The
decision to treat or to wait should also consider the likely avail-
ability of new antiviral drugs.
Recommendations
• All treatment-naïve patients with compensated 
disease due to HCV should be considered for therapy
(recommendation A1)
• Treatment should be scheduled, not deferred, for 
patients with significant fibrosis (METAVIR score F3 to
F4) 
(recommendation A1)
• In patients with less severe disease, the indication
for and timing of therapy can be individualized 
(recommendation B1)4 vol. 60 j 392–420
Table 2. Sustained virological response rates in phase III trials of boceprevir and telaprevir in HCV genotype 1 treatment-naïve patients.
Study Sustained virological 
response (%)
SPRINT-2
PegIFN/RBV 48 wk 38
PegIFN/RBV 4 wk then PegIFN/RBV + BOC response guided duration 63
PegIFN/RBV 4 wk then PegIFN/RBV + BOC 44 wk  66
ADVANCE
PegIFN/RBV 48 wk 44
PegIFN/RBV + TVR 8 wk then PegIFN/RBV response guided duration 69
PegIFN/RBV + TVR 12 wk then PegIFN/RBV response guided duration 75
ILLUMINATE (patients with an eRVR only)
PegIFN/RBV + TVR 12 wk then PegIFN/RBV 12 wk 92
PegIFN/RBV + TVR 12 wk then PegIFN/RBV 36 wk 88
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Phase III data on telaprevir and boceprevir in treatment-naïve
genotype 1 infection
In the phase III trials of BOC and TVR in HCV-1 treatment-naïve
patients, triple therapy regimens achieved higher SVR rates than
PegIFN/RBV dual therapy.
In the SPRINT-2 study of BOC, patients were randomized to
three treatment arms [37]. All patients received 4 weeks of
lead-in treatment with PegIFN/RBV. Subsequent treatment was
determined by the outcome of randomization to one of three
treatment arms. Group 1 (control arm) received an additional
44 weeks of PegIFN/RBV plus placebo. Group 2 (BOC response-
guided arm) received PegIFN/RBV plus BOC 800 mg three times
daily. Treatment duration was guided by on-treatment virological
response, so that patients who were HCV RNA undetectable at
week 8 and 24 stopped all drugs at week 28, while patients
who were HCV RNA detectable at any time point between week
8 and 24 stopped BOC at week 28, but then continued PegIFN/
RBV for a total treatment duration of 48 weeks. Group 3 (ﬁxed
duration BOC arm) received 44 weeks of PegIFN/RBV plus BOC.
The SVR rates were 38%, 63%, and 66% in groups 1, 2, and 3
respectively (Table 2). Similar SVR rates were achieved by the
proportions of groups 2 and 3 patients who were HCV RNA unde-
tected fromweek 8 through 24, whether they stopped all drugs at
week 28 after 24 weeks triple therapy (part of Group 2) or contin-
ued treatment until week 48 with 44 weeks triple therapy (Group
3) (SVR rates 96% in both groups). However, in patients where
HCV RNA was still detected at week 8, SVR rates were lower
when BOC was stopped at week 28 (with continuation of dual
therapy) than when it was continued as triple therapy until week
48 (SVR rates 66% vs. 75%). Based on these ﬁndings, and on a post
hoc analysis of individual patient data undertaken by the Euro-
pean Medicines Agency (EMA), the recommended response-
guided therapy for HCV-1 naïve patients receiving BOC as part
of triple therapy is as follows:
(1) Patients who are HCV RNA undetectable at week 8 and
remain undetectable at week 24 can stop all drugs at week
28.
(2) Patients with detectable HCV RNA at any time point
between week 8 and 24, should continue triple therapyJournal of Hepatology 201until week 36, then BOC should be stopped and PegIFN/
RBV continued until week 48.
(3) Response-guided therapy should be avoided in the pres-
ence of cirrhosis, where the recommended treatment sche-
dule is a 4 week lead-in phase of PegIFN/RBV followed by
44 weeks of PegIFN/RBV plus BOC. This recommendation
stems from caution rather than from detailed data in this
category of patients.
The 4 week PegIFN/RBV lead-in phase permits an assessment
of patient adherence and tolerance of treatment, and also an
assessment of the so-called ‘IFN-a sensitivity’ of the patient, thus
providing some estimate of the chances of an SVR in treatment-
naïve patients receiving BOC. In the SPRINT-2 study, patients
with less than a 1 log10 IU/ml decline in HCV RNA at week 4
had SVR rates of 4%, 28%, and 38% in groups 1, 2, and 3 respec-
tively. In contrast, SVR rates were high in patients with a more
than 1 log10 IU/ml decline: 51%, 81%, and 79% in groups 1, 2,
and 3, respectively. Indeed, SVR rates in patients reaching HCV
RNA undetectability during the lead-in phase were not increased
by the addition of BOC: 97%, 90%, and 90% in groups 1, 2, and 3,
respectively.
TVR for treatment-naïve patients was investigated in two
phase III trials, ADVANCE and ILLUMINATE. In ADVANCE [38],
treatment-naïve patients were enrolled and randomized into
three treatment groups: Group 1 (control, PR) received PegIFN/
RBV plus placebo for 48 weeks. Group 2 (T8PR) received 8 weeks
of triple therapy with TVR 750 mg/Q8h plus PegIFN/RBV followed
by a response-guided tail of PegIFN/RBV. Group 3 (T12PR)
received 12 weeks of triple therapy with TVR 750 mg/Q8h plus
PegIFN/RBV followed by a response guided tail of PegIFN/RBV.
In both the T8PR and the T12PR arms, treatment duration was
based on HCV RNA values at week 4 and 12. Patients in whom
HCV RNA was undetectable at week 4 to 12, the so-called
extended rapid virological response (eRVR; Table 3), stopped
treatment at week 24, while those in whom HCV RNA was detect-
able at either of these time points continued PegIFN/RBV up to
week 48. The SVR rates were 44%, 69%, and 75% in the PR,
T8PR, and T12PR groups, respectively (Table 2). Patients with
an eRVR achieved extremely high SVR rates with the 24 week
treatment arm both in the T8PR arm (83%) and in the T12PR
arm (89%). In the few patients in the PR arm who achieved eRVR
(only 8%), the SVR rate was also extremely high (97%). In patients4 vol. 60 j 392–420 397
Table 3. Monitoring of on-therapy response during dual or triple therapy: deﬁnitions of virological response levels.
Drug combination/response level Abbreviation Definition
PegIFN/RBV
Rapid virological response RVR Undetectable HCV RNA in a sensitive assay at week 4 of therapy 
Early virological response EVR HCV RNA detectable at week 4 but undetectable at week 12, maintained up to 
end of treatment 
Delayed virological response DVR More than 2 log10 IU/ml decrease from baseline but detectable HCV RNA at week 
12, then undetectable at 24 wk and maintained up to end of treatment 
Null response NR Less than 2 log10 IU/ml decrease in HCV RNA level from baseline at 12 wk of 
therapy
Partial response PR More than 2 log10 IU/ml decrease in HCV RNA level from baseline at 12 wk of 
therapy but HCV RNA detectable at 24 wk
Breakthrough* BT Reappearance of HCV RNA at any time during treatment after a negative result or 
increase of 1 log10 IU/ml from nadir
PegIFN/RBV + TVR
Extended rapid virological response eRVR Undetectable HCV RNA in a sensitive assay at week 4 and 12 of therapy 
PegIFN/RBV + BOC
Early response ER Undetectable HCV RNA in a sensitive assay at week 8 of therapy (after 4 wk of 
BOC)
Late response LR Detectable HCV RNA in a sensitive assay at week 8 of therapy, but negative at 
week 12 (after 8 wk of BOC)
⁄Deﬁnition applies also to TVR and BOC regimens.
Clinical Practice Guidelineswithout an eRVR, the SVR rates were 39%, 50%, and 54% in the PR,
T8PR, and T12PR arms respectively.
These data were the foundation for the phase III optimization
study ILLUMINATE [39], which used a randomized study design
to assess the relative beneﬁt to patients achieving an eRVR of fol-
lowing 12 weeks of TVR plus PegIFN/RBV triple therapy with
either 12 or 36 weeks of PegIFN/RBV dual therapy. All patients
received 12 weeks of TVR 750 mg/Q8h plus PegIFN/RBV. Patients
with an eRVR were randomized to receive either a further
12 week tail of PegIFN/RBV (T12PR24) or a 36 week tail of Peg-
IFN/RBV (T12PR48). In the 60% of patients with an eRVR, the
SVR rates were 92% in the T12PR24 cohort and 87.5% in the
T12PR48 cohort (Table 2). Based on the results of these 2 studies,
overall treatment duration with triple therapy containing TVR
can be shortened to 24 weeks in naïve patients with an eRVR,
while treatment needs to be continued until week 48 in those
without an eRVR. In patients with cirrhosis, treatment with Peg-
IFN/RBV is to be continued until week 48 regardless of HCV RNA
kinetics since, in the ILLUMINATE trial, SVR rate in cirrhotics with
an eRVR was higher when therapy was continued until week 48
(92% vs. 67%). Thus, based on these three phase III studies, which
evaluated BOC or TVR in genotype 1 treatment-naïve patients, it
can be concluded that triple therapy comprising PegIFN/RBV with
either of the PIs is the treatment of choice.
A potential role for dual therapy in genotype 1 infection
Dual therapy may be appropriate for selected treatment-naïve
patients with baseline features predicting a high likelihood of
RVR and SVR to PegIFN/RBV. Cost savings and better tolerability
of dual therapy must be taken into account. Moreover, occasional
patients may have co-morbid conditions which require medica-
tion known or predicted to have adverse drug-drug interaction
with the ﬁrst-generation PIs. In the pivotal clinical trials for reg-
istration of PegIFN/RBV therapy, SVR was achieved in 46% and
42% of patients infected with HCV genotype 1 when treated with
pegylated IFN-a2a or pegylated IFN-a2b and ribavirin, respec-398 Journal of Hepatology 201tively [40–42]. SVR rates in these patients were slightly higher
in Europe than in the US. These results were conﬁrmed in the
IDEAL trial that compared two approved treatment regimens in
the United States: 41% of patients achieved SVR when treated
with pegylated IFN-a2a (180 lg/week) plus weight-based ribavi-
rin (1.0 to 1.2 g/day) for 48 weeks, vs. 40% of patients treated with
pegylated IFN-a2b (1.5 lg/kg/week) plus weight-based ribavirin
(0.8 to 1.4 g/day) for the same period (SVR rates not signiﬁcantly
different) [43].
In addition to those patients who may have a contraindication
to PI treatment, dual treatment with PegIFN/RBV can achieve
very high SVR rates in selected patients with highly IFN-a-sensi-
tive infection, an approach which can avoid the cost and
additional side-effects associated with PI treatment [44]. For
instance, post hoc subgroup analysis showed that, in HCV geno-
type 1 patients with the favourable IL28B genotype, dual therapy
obtained similar SVR rates to triple therapy including BOC. This
was also true for patients achieving an RVR during the PegIFN/
RBV week 4 lead-in phase. TVR can also be used with a 4 week
lead-in period of dual therapy, possibly for those with a favour-
able IL28B genotype. Under that situation, achievement of RVR
could justify the continuation of dual PegIFN/RBV treatment
without the addition of TVR. In this highly IFN-a-responsive cat-
egory of patients, the main advantage of triple therapy is the pos-
sibility of shortening overall treatment duration to 24 weeks with
the TVR-containing regimen and to 28 weeks with BOC-contain-
ing regimen. With dual therapy, treatment should only be abbre-
viated if the baseline HCV RNA level is less than 400,000 IU/ml, an
RVR is achieved and no further negative predictor of treatment
outcome is present.
Drug dosing in HCV genotype 1 therapy
Pegylated IFN-a2a should be used at the dose of 180 lg/week,
whereas pegylated IFN-a2b should be used at the weight-based
dose of 1.5 lg/kg/week. In triple therapy, ribavirin dose should
be 1000–1200 mg/day based on body weight for pegylated4 vol. 60 j 392–420
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IFN-a2a, and 800–1400 mg/day based on body weight for pegy-
lated IFN-a2b. TVR is dosed 750 mg/every 8 h, though recently
presented clinical trial data showed that 12-hourly dosing
(1125 mg 12 hourly) does not have inferior efﬁcacy in compari-
son with the licensed schedule (750 mg 8 hourly) [45]. BOC is
dosed 800 mg/every 7–9 h. Both PIs need to be taken with food.
Each TVR dose needs to be taken with a 20 g fat content snack.
In phase III studies, TVR was associated with peg IFN-a2a, while
BOC was studied with both pegylated IFNs. In a randomised
study, TVR therapy achieved equivalent SVR rates used with
either of these pegylated IFNs [46].
Recommendations
• The combination of PegIFN/RBV and TVR or BOC is
the approved standard of care for chronic hepatitis C
genotype 1 (recommendation A1). There is no head-
to-head comparison to allow recommendation of TVR or
BOC as preferred therapy
• Patients with cirrhosis should never receive abbreviated
treatment in BOC or TVR treatment regimens 
(recommendation B1)
• Selected patients with high likelihood of SVR to PegIFN/
RBV or with contraindications to BOC or TVR can be
treated with dual therapy 
• When lead-in is used to identify patients with IFN-α-
sensitive infection, the possibility of continuation of dual
therapy should have been discussed with the patient
prior to initiation of treatment 
(recommendation B2)
• Both pegylated IFN-α molecules, pegylated IFN-α2a
(180 μg/wk) and pegylated IFN-α2b (1.5 μg/kg/wk), can
be used in dual or triple therapy 
(recommendation B1)
 
• Ribavirin should be dosed following the pegylated IFN-α
label for triple therapy 
(recommendation B2)
• Ribavirin should be given at a weight-based dose of 15
mg/kg in dual therapy 
(recommendation B2)
Treatment-naïve patients with genotypes 2, 3, 4, 5, or 6
In patients infected with HCV genotypes 2 and 3, SVR was
achieved in the pivotal trials in 76% and 82% of cases with pegy-
lated IFN-a2a plus ribavirin and pegylated IFN-a2b plus ribavirin,
respectively. Some real-life studies have recently reported lower
SVR rates for genotype 3 infection [47,48].
Patients with HCV genotype 4 were under-represented in the
pivotal trials of PegIFN/RBV. Therefore most data on SVR rates
derive from subsequent studies. Reported SVR rates range
between 43% and 70% with the 48 week schedule of pegylated
IFN-a plus weight-based ribavirin. Some studies have shown
lower SVR rates in HCV genotype 4 patients of European descent
compared with patients from other geographical areas [49].
In patients infected by HCV genotype 2, 3, 4, 5, or 6, the stan-
dard of care regimen consists of the combination of either of theJournal of Hepatology 201two pegylated IFN-a’s with ribavirin. Pegylated IFN-a2a should
be used at the dose of 180 lg/week, whereas pegylated IFN-
a2b should be used at the weight-based dose of 1.5 lg/kg/week.
The ribavirin dose depends on the HCV genotype. Patients
infected with HCV genotypes 4, 5, and 6 should receive a
weight-based dose of ribavirin, i.e. 15 mg/kg body weight.
Patients infected with genotypes 2 and 3 can be treated with a
ﬂat dose of 800 mg of ribavirin daily, but those with a body mass
index (BMI) beyond 25 or who have baseline factors suggesting
low responsiveness (insulin resistance, metabolic syndrome,
severe ﬁbrosis or cirrhosis, older age) should receive a weight-
based dose of ribavirin.
There is no indication to the use of ﬁrst-generation PIs in
patients with non-1 genotype HCV infection.
Recommendations
• The combination of pegylated IFN-α and ribavirin is
the approved standard of care for chronic hepatitis C
genotype 2, 3, 4 ,5, and 6 
(recommendation A1)
• Ribavirin should be given at a weight-based dose of 15
mg/kg for genotypes 4, 5, and 6 and at a flat dose of
800 mg/day for genotypes 2 and 3 
(recommendation A2)
• Patients with genotypes 2 and 3 with baseline factors
suggesting low responsiveness should receive 
weight-based ribavirin at the dose of 15 mg/kg 
(recommendation C2)Treatment monitoring
Treatment monitoring includes monitoring of treatment efﬁcacy
and of safety and side effects.
Monitoring of treatment efﬁcacy
Monitoring of treatment efﬁcacy is based on repeated measure-
ments of HCV RNA levels. A sensitive, accurate assay with a broad
dynamic range of quantiﬁcation should be used. The same assay,
ideally from the same laboratory, should be used in each patient
to measure HCV RNA at different time points, in order to assure
consistency of results [50–52]. In order to monitor treatment efﬁ-
cacy and guide decisions on treatment duration, HCV RNA level
measurements should be performed at speciﬁc time points. Mea-
surements should only be made if and when the result of the
measurement will have some inﬂuence on the scheduled treat-
ment, i.e. if the result will determine that treatment should be
abandoned (futility rules), that treatment can be abbreviated
(response-guided therapy), or that treatment has been successful
(end of treatment and post-treatment SVR assessment).
In dual therapy, HCV RNA levels should be assessed at
baseline, week 4, week 12, week 24, end of treatment, and 12
or 24 weeks after the end of therapy in order to assess the SVR.
In triple therapy with BOC, HCV RNA should be measured at
weeks 4, 8, 12, 24, end of treatment, and 12 or 24 weeks after
the end of therapy. For BOC therapy, here and elsewhere in the
Guidelines, the timing of RNA quantitation refers to weeks after
commencement of the dual therapy lead-in. In triple therapy4 vol. 60 j 392–420 399
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with TVR (here assuming no dual therapy lead-in), HCV RNA
should be assessed at weeks 4, 12, 24, end of treatment, and 12
or 24 weeks after the end of therapy.
For patients receiving dual therapy, a low vs. high baseline
HCV RNA level may be used to guide treatment decisions based
on the on-treatment virological response. There is no current
agreement on the best discriminating HCV RNA level, which
ranges between 400,000 and 800,000 IU/ml (5.6–5.9 log10 IU/
ml) [40,53–59].
Stopping (futility) rules
With dual therapy, treatment should be stopped at week 12 if the
HCV RNA decrease is less than 2 log10 IU/ml. The SVR rate
achieved by treatment continuation in these patients is less than
2%. In patients with detectable HCV RNA at week 24, there is a
very small chance of SVR (1–3%) and treatment should be
stopped [40,53,58,60]. This stopping rule was deﬁned by analysis
of data at a time when detection assays were less sensitive than
the currently available assays. Logically, treatment should beA PegIFN/RBV + TVR
Week 0 4
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RNA
PegIFN/RBV
Week 0 4 8
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RNA
Undetected
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<1000 IU/ml
Detected
>1000 IU/ml STOP
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*only in fibrosis stage F0-F3 treatment naïves and relapsers
ºfibrosis stage and previous response guide BOC duration
Fig. 1. Management algorithms. For the use of triple therapy comprising PegIFN/RB
virological response; ER, early response; LR, late response.
400 Journal of Hepatology 201continued for those patients with undetectable RNA using cur-
rent assays.
In triple therapy with BOC, stopping rules have been retro-
spectively derived from analysis of the SPRINT-2 study. All drugs
should be stopped if HCV RNA is >100 IU/ml at treatment week
12, if HCV RNA is detectable at treatment week 24, and in case
of viral breakthrough (BT) later on.
In TVR-based regimens the stopping rules were retrospec-
tively modelled from the ADVANCE database. All drugs should
be stopped if HCV RNA is >1000 IU/ml at week 4 or 12 of therapy,
and in case of BT later on.
Virological response-guided triple therapy
The evidence and principles for response-guided therapy of treat-
ment-naïve patients were discussed in section ‘Phase III data on
telaprevir andboceprevir in treatment-naïve genotype1 infection’.
The treatment algorithms for BOC and TVR, including
guidance for response-guided therapy and stopping rules, are
presented in Fig. 1A and B.PegIFN/RBV
12 24
PegIFN/RBV + BOC
12 24
Undetected
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Virological response-guided dual therapy
PegIFN/RBV treatment duration can be tailored to the on-treat-
ment virological response. Upon treatment, HCV RNA levels
should be assessed at three time points, regardless of the HCV
genotype: baseline and weeks 4 and 12. The likelihood of SVR
is directly proportional to the speed of HCV RNA disappearance
(Fig. 2).
Treatment should be stopped at week 12 if the HCV RNA
decrease is less than 2 log10 IU/ml. Patients with a more than 2
log10 drop or an undetectable HCV RNA at week 12 can be classi-
ﬁed into three groups according to their virological response
(Table 3).
(1) The rapid virological response (RVR) is deﬁned as an
undetectable HCV RNA at week 4 of therapy.
(2) The early virological response (EVR) is deﬁned as an HCV
RNA, which is undetectable at week 12. In some literature,
this is referred to as complete EVR (cEVR).
(3) The delayed virological response (DVR) is deﬁned as a
more than 2 log10 drop with detectable HCV RNA at week
12, and undetectable HCV RNA at week 24. In some litera-
ture, this is referred to as partial EVR (pEVR).
Reappearance of HCV RNA at any time during treatment after
virological response is classiﬁed as breakthrough (BT).
The following treatment durations should be applied accord-
ing to the virological response:
(1) Patients infected with HCV genotype 1, with an RVR can be
treated for 24 weeks. A recent meta-analysis suggested
that this applies only to those with a low baseline HCV
RNA level. As uncertainties remain as to which threshold
should be used to distinguish low and high baseline HCV
RNA levels, patients infected with HCV genotype 1 (and
possibly also those infected with genotype 4) with aDVR, delayed virological response; EVR, early virological response; RVR, rapid vir
Clearance of  
infected cells 
Phase 1 (24-48 h)
Phase 2 
HCV RNA 
4 
Limit of detection 
≤50 (IU/ml) 
W
12 24 0 1 
Likelihood of 
RVR EVR DVR 
Fig. 2. Likelihood of SVR according to viral response in the ﬁrst weeks of dual thera
Journal of Hepatology 201baseline viral level <400,000 IU/ml should be treated for
24 weeks, whereas it is reasonable to prolong therapy for
a total of 48 weeks in patients with a higher baseline
HCV RNA level [41,56,57,59,61,62]. Some suggest a higher
threshold.
(2) Patients infected with HCV genotype 1 (and possibly also
those infected with genotype 4) and who achieve an EVR
without an RVR should be treated for 48 weeks [61,63–68].
(3) Patients with HCV genotype 1 and a delayed virological
response (DVR) can be treated for 72 weeks, provided that
their HCV RNA is undetectable at week 24. Insufﬁcient data
exist for other genotypes [61,63–68]. (Recommendations
(2) and (3) clearly refer to patients with genotype 1 infec-
tion who are being treated in a setting where PIs are
unavailable or contraindicated.)
(4) In patients infected with HCV genotypes 2 and 3 with an
RVR and low baseline viral load (<400,000 IU/ml), shorten-
ing of treatment duration to 16 weeks can be considered at
the expense of a slightly higher chance of post-treatment
relapse [54,69–72].
(5) In patients with HCV genotypes 2 and 3 who have
advanced ﬁbrosis, cirrhosis or cofactors affecting response
(insulin resistance, metabolic syndrome, non-viral steato-
sis) shortening of treatment duration to 16 weeks should
not be considered, even if they have low baseline HCV
RNA and RVR. There is insufﬁcient evidence of an equal
efﬁcacy [55,73–75].
(6) Patients with genotypes 2 and 3 without RVR and with
negative cofactors affecting response could be treated for
48 weeks, provided that their HCV RNA is undetectable
at week 24 [41,76].
For patients receiving dual PegIFN/RBV therapy, response-
guided treatment proﬁles are outlined in Fig. 3 for HCV genotype
1 and Fig. 4 for HCV genotypes 2 and 3.ological response. 
eeks 
48 72 
SVR
py with PegIFN/RBV.
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Fig. 3. Response-guided therapy in patients with genotype 1 receiving dual therapy with PegIFN/RBV (applies also to genotype 4 at a B2 grade of evidence). DVR,
delayed virological response; EVR, early virological response; Neg, HCV RNA not detected; NR, null response; Pos, HCV RNA detected; PR, partial response; RVR, rapid
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Recommendations
• A real-time PCR-based assay with a lower limit of 
detection of <15 IU/ml should be used to monitor triple
therapy (recommendation B1)
• During triple therapy in HCV genotype 1 patients, HCV
RNA measurements should be performed at weeks 4, 8,
12, 24, and end of treatment when giving BOC, and at
weeks 4, 12, 24, and end of treatment when giving TVR
(recommendation A2)
• During dual therapy in any HCV genotype, HCV RNA
levels should be assessed at baseline, weeks 4, 12, 24
and end of treatment 
(recommendation A2)
• The end-of-treatment virological response and the SVR
at 12 or 24 weeks after the end of treatment must be
assessed (recommendation A1)
• Whether the baseline HCV RNA level is low or high
may be a useful criterion to guide treatment decisions
during dual therapy (recommendation B2). The safest
threshold level for discriminating low and high baseline
HCV RNA is 400,000 IU/ml (recommendation C2)
• Dual therapy for all HCV genotypes should be stopped
at week 12 if the HCV RNA decrease is less than 2
log10 IU/ml and at week 24 if HCV RNA is still detectable
(recommendation B1)
• Triple therapy with BOC should be stopped if HCV RNA
is >100 IU/ml at treatment week 12 or if HCV RNA is
detectable at treatment week 24 
(recommendation B1)
• Triple therapy with TVR should be stopped if HCV
RNA is >1000 IU/ml at weeks 4 or 12 of therapy 
(recommendation B1)
• Dual therapy duration should be tailored to the on-
treatment virological response at weeks 4 and 12. The
likelihood of SVR is directly proportional to the rapidity
of HCV RNA disappearance (recommendation B1)
• For patients receiving dual therapy who achieve an
RVR and who have low baseline viral titre (<400,000 IU/
ml), treatment for 24 weeks (genotype 1) or 16 weeks
(genotype 2/3) can be considered. If negative predictors
of response (i.e. advanced fibrosis/cirrhosis, metabolic
syndrome, insulin resistance, hepatic steatosis) are
present, published evidence for equal efficacy of 
shortened treatment is lacking (recommendation B2)
• Patients receiving dual therapy with genotypes 2 or
3, and with any adverse predictor of SVR, and who
achieve an EVR or a DVR without an RVR, can be
treated for 48 weeks (recommendation B2)
• Genotype 1 patients receiving dual therapy who 
demonstrate a DVR can be treated for 72 weeks, 
provided that their HCV RNA is undetectable at week 24
(recommendation B2)Journal of Hepatology 201Monitoring treatment safety
Flu-like symptoms are often present after pegylated IFN-a injec-
tions. They are easily controlled by paracetamol and tend to
attenuate after 4–6 weeks of therapy. At each visit, the patients
should be assessed for clinical side effects, such as severe fatigue,
depression, irritability, sleeping disorders, skin reactions, and
dyspnoea. Thyroid stimulating hormone (TSH) levels should be
measured every 12 weeks while on therapy [77].
Hematological side effects of pegylated IFN-a and ribavirin
include neutropenia, anemia, thrombocytopenia and lymphope-
nia. These parameters should be assessed at weeks 1, 2, and 4
of therapy and at 4 to 8 week intervals thereafter. Both BOC
and TVR increase the risk of anemia, especially in patients with
liver cirrhosis.
Dermatological adverse events (AEs) are frequent during HCV
therapy, in both dual and PI-containing regimens. TVR can cause
skin rashes, which may be severe and may demand early termi-
nation of the TVR component of therapy. In TVR trials, dermato-
logical AEs with TVR-based triple therapy were generally similar
to those observed with PegIFN/RBV but approximately half of
TVR-treated patients reported a rash [38]. More than 90% of these
were grade 1 or 2 (mild/moderate), and in the majority of cases,
progression to a more severe grade did not occur. In a small num-
ber of cases (6%), rash led to TVR discontinuation, whereupon
symptoms commonly resolved. A few cases were classiﬁed as
severe cutaneous adverse reactions (SCAR), a group of rare condi-
tions that are potentially life-threatening. The TVR prescribing
information does not suggest TVR discontinuation for grade 1
or 2 rash, which can be treated using emollients/moisturizers
and topical corticosteroids. For grade 3 rash, the prescribing
information mandates immediate TVR discontinuation, with riba-
virin interruption (with or without pegylated IFN-a) within
7 days of stopping TVR if there is no improvement (or sooner if
it worsens). In case of suspicion or conﬁrmed diagnosis of SCAR,
all medication must be discontinued.RecommendationsTreatment dose reductions
The pegylated IFN-a dose should be reduced in case of severe
side effects, such as clinical symptoms of severe depression,
and if the absolute neutrophil count falls below 750/mm3, or
the platelet count falls below 50,000/mm3. When using pegylated
IFN-a2a, the dose can be reduced from 180 lg/week to 135 lg/
week, and then to 90 lg/week. When using pegylated IFN-a2b,
the dose can be reduced from 1.5 lg/kg/week to 1.0 lg/kg/week
and then to 0.5 lg/kg/week. Pegylated IFN-a should be stopped
in case of marked depression, if the neutrophil count falls below
500/mm3 or the platelet count falls below 25,000/mm3. If and
when neutrophil or platelet counts rise from those nadir values,
treatment can be restarted, but at a reduced dose. Interferon
treatment interruptions should be as brief as possible. Prolonged
interruption of IFN administration will reduce treatment efﬁcacy
and may contribute to emergence of PI resistance during triple
therapy. Thus, in cases where neutrophil and platelet counts
determine that there is signiﬁcant delay in IFN resumption,
treatment should be abandoned. There is no role for prolonged
IFN-free dual therapy with ribavirin and ﬁrst generation PIs for
genotype 1 infection. If signiﬁcant anemia occurs (hemoglobin
<10 g/dl), the dose of ribavirin should be adjusted downward4 vol. 60 j 392–420 403
Clinical Practice Guidelines
by 200 mg at a time. Hemoglobin decline is accelerated by the
addition of ﬁrst generation PIs to PegIFN/RBV. A more rapid
reduction of dose may be required for patients with rapidly
declining hemoglobin, particularly if the baseline hemoglobin
was low, and particularly during triple therapy. Ribavirin admin-
istration should be stopped if the hemoglobin level falls below
8.5 g/dl. Alternatively, growth factors can be used to enable high
doses of pegylated IFN-a and/or ribavirin to be maintained (see
below) [40,41,53,77–82].
Treatment should be promptly stopped in case of a hepatitis
ﬂare (ALT levels above 10 times normal, if not already present
at the time of starting treatment) or if a severe bacterial infection
occurs at any site, regardless of neutrophil count.
BOC or TVR doses should not be reduced during therapy, as
this will favour the development of antiviral drug resistance.
For both PIs, treatment should either be stopped completely,
because of side effects, or be continued at the same dose provided
that adjuvant therapy is prescribed. The decision should take into
consideration the type of side effects and the likelihood of achiev-
ing SVR with on-going therapy. Once BOC or TVR have been
stopped, they should never be reintroduced in the same course
of treatment.• HCV treatment should be delivered within a 
multidisciplinary team setting 
(recommendation A1)
• HCV infected patients should be counselled on 
the importance of adherence for attaining an SVR 
(recommendation A1)
 
• In patients with socioeconomic difficulties and 
in migrants, social support services should 
be a component of HCV clinical management 
(recommendation B2)
• In persons who actively inject drugs, access to harm
reduction programs is mandatory 
(recommendation A1)
• Peer-based support should be evaluated as a means to
improve HCV clinical management 
(recommendation B2)
• HCV treatment can be considered also for patients
actively using drugs, provided they wish to receive 
treatment and are able and willing to maintain regular
appointments. Also, the potential for drug-drug 
interactions involving prescribed and non-prescribed
drugs needs to be considered 
(recommendation A1)Measures to improve treatment success rates
Simple measures to enhance adherence to treatment should be
implemented since this has been shown to be associated with
signiﬁcantly higher SVR rates.
Treatment adherence
Full adherence to both pegylated IFN-a and ribavirin is associated
with improved SVR rates. It is recommended that dose reductions
are reviewed and that the optimum dose is restored as soon as
possible in order to attain and sustain maximum exposure to
each drug. Adherence to HCV therapy has been deﬁned as receipt
of P80% of scheduled pegylated IFN-a and ribavirin doses for
P80% of the treatment period, but this deﬁnition does not distin-
guish between missed doses and treatment discontinuations
[83]. Suboptimal IFN exposure is mainly due to early treatment
discontinuation rather than to occasional missed doses [84]. It
is of note that both physicians [85] and individuals [86] overesti-
mate adherence to HCV therapy. Suboptimal exposure to IFN may
also permit the emergence of resistance-associated variants in
regimens containing a DAA, especially during the early phase of
treatment.
Before starting antiviral therapy, patients must be instructed
about the schedule and the side effects to be expected during
treatment. Patients should also be instructed about the
preventive and therapeutic measures to ameliorate these side
effects, for example by using antipyretics, analgesics, or
antidepressants (see below). Regular follow-up visits must be
scheduled so that treatment progress and management of side
effects can be discussed. Easy access to physicians or to special-
ized nursing staff in case of side effects should be facilitated in
order to reduce discontinuation rates to a minimum. Patient
recall procedures in cases of missed appointments should be
instituted.
Examples of strategies that have been successful for
enhancing clinical assessment, management adherence and
achievement of SVR include hospital-based [87] and primary
care-based integrated care [88], community-based tele-health404 Journal of Hepatology 201[89], nurse-led education [90], psychoeducation [91], directly
observed therapy [92–95], peer support groups [88,96] and
peer support workers [97]. The key element of effective HCV
clinical management within all these settings is access to a
multidisciplinary team, generally including clinician and nurs-
ing clinical assessment and monitoring, drug and alcohol ser-
vices, psychiatric services, and social work and other social
support services (including peer support, if available). Mea-
sures to increase adherence are interdisciplinary HCV educa-
tion and monitoring services and, particularly, the help of a
dedicated nurse [98,99]. For foreign patients, the language
and comprehension difﬁculties should be addressed before
starting treatment.
To maximize the likelihood of beneﬁt for patients who
begin new HCV treatment regimens, resources should be
devoted to patient pre-treatment assessment and preparation,
as well as to on-treatment adherence monitoring and support
[100,218].
RecommendationsCorrection of cofactors
Body weight. High body weight (BMI) adversely inﬂuences the
response to PegIFN/RBV, even after dose adjustments [101]. Body
weight reduction prior to therapy is recommended but the data
suggesting that this may be associated with better SVR rates is
scanty.
Lipids. The HCV life cycle is tightly linked to lipid metabolism.
Thus, some cholesterol lowering drugs have been shown to inhi-
bit HCV replication and may improve response rate to treatment,
but the data are limited.4 vol. 60 j 392–420
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Alcohol. Alcohol consumption has an impact on treatment adher-
ence [102]. Patients should therefore be advised to stop or to
reduce alcohol consumption before start of treatment. HCV
patients who consume alcohol but are able to adhere to a full
course of HCV treatment have similar SVR rates to non-drinkers
[103,104]. Treatment for patients not able to abstain from alcohol
should be ﬁtted to the individual, focussing on their ability to
adhere to medication and appointments. Hepatitis C patients
with on-going alcohol consumption during treatment proﬁt from
additional support during antiviral therapy [102–105].
Metabolic syndrome. Insulin resistance and type 2 diabetes,
independently of their pathogenesis, accelerate liver disease
progression and increase the risk for the development of
HCC. They also reduce response to the standard combination
of PegIFN/RBV. However, it seems unlikely that they may also
decrease response to PI-containing regimens [106]. HCV infec-
tion per se does not carry an increased risk of metabolic syn-
drome, but is able to perturb glucose homeostasis through
several direct and indirect mechanisms, leading to both hepa-
tic and extrahepatic insulin resistance. This translates into an
increased risk for development of type 2 diabetes in suscepti-
ble persons. HCV may also cause hepatic steatosis, especially
in patients infected with genotype 3, although the clinical
impact of ‘viral’ steatosis is debated. Possibly as a result of
HCV-induced insulin resistance, and despite a paradoxically
favourable lipid proﬁle, the cardiovascular risk is moderately
increased in chronic hepatitis C. Thus, targeted lifestyle and
pharmacological measures are warranted in chronic hepatitis
C with metabolic alterations. However, results of attempts to
increase the SVR rate to PegIFN/RBV by the use of insulin sen-
sitizers are not conclusive and do not justify the use of this
class of drugs for this purpose [107].
Supportive therapy
Growth factors. It has been suggested that the use of hemato-
logic growth factors is helpful in limiting the need for treat-
ment dose reductions. Recombinant erythropoietin (EPO) can
be used to maintain or to improve hemoglobin levels in order
to avoid ribavirin dose reductions or interruptions. Although
no prospective trials have been designed to date to deﬁnitely
demonstrate that the use of EPO has a positive impact on SVR,
it is widely used to enable high doses of ribavirin to be main-
tained and to improve the quality of life during therapy [108].
EPO can be administered when the hemoglobin level falls
below 10 g/dl, and titrated thereafter to maintain hemoglobin
levels between 10 and 12 g/dl. However, no general consensus
exists regarding the use of EPO, particular concerning optimal
dosing, treatment beneﬁts, potential risks and cost-effective-
ness, and the cost of EPO is not reimbursed in many European
countries [109,110]. Anemia is more profound during PI-base
triple therapy than during PegIFN/RBV treatment. In a pro-
spective study, which compared EPO administration vs. ribavi-
rin dose reduction in response to anemia during BOC-based
triple therapy, SVR rate was unaffected by ribavirin dose
reduction. The results imply that ribavirin dose reduction
should be the initial response to anemia in this setting, andJournal of Hepatology 201that anemia-driven dose reduction does not compromise the
likelihood of SVR [111].
At the moment, there is no clear evidence to indicate that neu-
tropenia during PegIFN/RBV therapy has adverse effects. While
administration of granulocyte colony stimulating factor (G-CSF)
may enable patients to remain on or resume optimal HCV ther-
apy, in a systematic review there was weak evidence that this
improves the likelihood of SVR compared with IFN dose reduc-
tion. Adverse effects of G-CSF are mild. An economic evaluation
was inconclusive [112].
Treatment discontinuation rates due to thrombocytopenia
are rare and patients with low platelet counts can generally
be initiated on PegIFN/RBV therapy without an increase in
major bleeding episodes. Thrombopoietin receptor agonists
can raise blood platelet counts. Two are currently available
i.e. romiplostim and eltrombopag. The latter has been shown
to increase platelet counts in thrombocytopenic patients with
HCV-related cirrhosis [113]. Both agents have been granted
marketing authorization for use in patients with primary
immune thrombocytopenia unresponsive to conventional treat-
ments. Clinical trials with these agonists are ongoing in HCV-
related thrombocytopenia [114]. There is FDA approval for
eltrombopag to be used to initiate and maintain IFN-a-based
antiviral treatment of HCV in patients with thrombocytopenia.
Approval was based solely on data derived from studies of
dual PegIFN/RBV therapy. Portal vein thrombosis is a potential
and feared complication of raised platelet counts in this set-
ting, particularly in patients with advanced cirrhosis. Thus,
the aim of supportive therapy should be to raise platelet
counts to a safe level but not into the normal range.
Antidepressants. Depression has a severe adverse impact on
health-related quality of life during PegIFN/RBV therapy and
was the most frequent reason for treatment discontinuation in
the pivotal trials. Patients with a history and/or signs of depres-
sion should be seen by a psychiatrist before therapy initiation
in order to assess the risk. They should be under psychiatry fol-
low-up thereafter if needed. Antidepressant therapy should be
initiated during therapy if felt appropriate, and appropriate fol-
low-up is required to decide whether IFN treatment interruption
is needed.
Poorer social functioning is associated with new-onset
depression during IFN treatment. Psychiatric co-morbidity is
not associated with lower adherence, reduced treatment com-
pletion, or reduced SVR during IFN treatment [218]. Relative
psychiatric contraindications to HCV therapy include acute
major and uncontrolled psychiatric disorders. Although data
are conﬂicting, studies show that prophylactic antidepressants
can reduce IFN-induced depression, particularly in those with
previous or ongoing depression. Depression-speciﬁc symptoms
are highly responsive to serotoninergic antidepressants. IFN-
associated psychiatric AEs can be managed without dose
adjustments or discontinuation of IFN [218]. Irritability and
anxiety resulting from IFN-induced sleep deprivation should
not be confused with depression and should be adequately
treated with anxiolytics rather than with hypnotics or antide-
pressants [115].4 vol. 60 j 392–420 405
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Recommendations
• Full adherence to all antiviral drugs should be the 
objective in order to optimize SVR rates and to reduce
the risk of emergence of specific drug resistance 
(recommendation A1)
• Body weight adversely influences the response to 
pegylated IFN-α and ribavirin (recommendation 
A2). Body weight reduction in overweight patients 
prior to therapy may increase likelihood of SVR 
(recommendation C2)
 
• Insulin resistance is associated with treatment failure for
dual therapy (recommendation B2). Insulin sensitizers
have no proven efficacy in improving SVR rates in
insulin-resistant patients 
(recommendation C2)
• Patients should be counselled to abstain from alcohol
during antiviral therapy 
(recommendation C2)
• In dual therapy, the use of EPO when the hemoglobin
level falls below 10 g/dl may reduce the need to reduce
ribavirin dose (which may, in turn, have reduced the
chance of achieving SVR) 
(recommendation C2)
• In patients receiving BOC/TVR-based triple therapy,
ribavirin dose reduction should be the initial response to
significant anemia 
(recommendation B1)
• There is no evidence that neutropenia during PegIFN/
RBV therapy is associated with more frequent infection
episodes (recommendation C2), or that the use of
G-CSF reduces the rate of infections and/or improves
SVR rates 
(recommendation B2)
• Patients with a history and/or signs of depression 
should be seen by a psychiatrist before therapy 
(recommendation C2). Patients who develop 
depression during therapy should be treated with 
antidepressants. Preventive antidepressant therapy
in selected subjects may reduce the incidence of 
depression during treatment, without any impact on the
SVR 
(recommendation C2)Post-treatment follow-up of patients who achieve an SVR
Non-cirrhotic patients who achieve an SVR should be retested for
HCV RNA at 48 weeks post-treatment. If HCV RNA is still not
detected, the infection can be considered as deﬁnitely eradicated
and HCV RNA need not be retested. As hypothyroidismmay occur
after stopping therapy, TSH levels should also be assessed 1 and
2 years after treatment. Patients with pre-existing cofactors of
liver disease (notably, history of alcohol drinking and/or type 2
diabetes) should be carefully and periodically subjected to a thor-
ough clinical assessment, as needed.406 Journal of Hepatology 201Cirrhotic patients who achieve an SVR should remain under
surveillance for HCC every 6 months by ultrasound, and for
oesophageal varices by endoscopy if varices were present at
pre-treatment endoscopy (though ﬁrst variceal bleed is seldom
observed after SVR). The presence of cofactors of liver disease,
such as history of alcohol drinking and/or type 2 diabetes may
determine that additional assessments are necessary.
Re-infection following successful HCV treatment
There remains some concern that re-infection due to recurrent or
persistent risk behaviour may negate the potential beneﬁt of
treatment. Reported rates of re-infection following successful
HCV treatment among patients at high risk, such as PWID, are
low, with estimates of 1–5% risk per year [116–120,218].
Recommendations
• Non-cirrhotic patients with SVR should be retested for
ALT and HCV RNA at 48 weeks post-treatment, then
discharged if ALT is normal and HCV RNA is negative
(recommendation C2)
• Cirrhotic patients with SVR should undergo surveillance
for HCC every 6 months by means of ultrasound 
(recommendation B1)
• Guidelines for management of portal hypertension
and varices should be implemented, though index 
variceal bleed is seldom seen in low-risk patients after
the achievement of SVR (unless additional causes
for ongoing liver damage are present and persist) 
(recommendation A2)
• Patients with ongoing drug use should not be excluded
from HCV treatment on the basis of perceived risk of
reinfection 
(recommendation B1)
• Following SVR, monitoring for HCV reinfection through
annual HCV RNA assessment should be undertaken on
PWID with ongoing risk behaviour 
(recommendation B2)Retreatment of non-sustained virological responders to pegylated
IFN- and ribavirin
There are a substantial number of patients with genotype 1 hep-
atitis C who have had previous therapy with pegylated or stan-
dard IFN-a and ribavirin who have not achieved an SVR with
that therapy. These patients can broadly be divided into three
groups according to the pattern of response and virological fail-
ure during dual therapy. This terminology is now routinely
applied in patient selection criteria for clinical trials, and in
description of outcomes of clinical trials.
(1) Virological relapse: Patients who have undetectable HCV
RNA at the end of treatment, but do not achieve an SVR.
(2) Virological partial response: Patients who have a
>2 log10 IU/ml drop in HCV RNA by 12 weeks of treatment,
but never achieve undetectable HCV RNA.4 vol. 60 j 392–420
• Patients infected with HCV genotype 1 who failed 
to eradicate HCV on prior therapy with PegIFN/
RBV should be considered for re-treatment with 
the triple combination of PegIFN/RBV and a PI 
(recommendation A1)
• The previous response to IFN-based therapy is 
an important predictor of success of triple therapy,
with relapsers having higher cure rates than partial
responders, who in turn have higher cure rates than
null responders. If the pattern of prior response to dual
therapy is not clearly documented, the patient should
not be treated with abbreviated response-guided 
therapy 
(recommendation A2)
• Patients with cirrhosis and prior null responders 
have a lower chance of cure and should not be 
treated with response-guided therapy with either PI
(recommendation B2)
• Patients infected with HCV genotypes other than 1
and who failed on prior therapy with non-pegylated
IFN-α, with or without ribavirin, can be re-treated with
pegylated IFN-α and ribavirin 
(recommendation B2)
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(3) Virological null response: Patients who have a <2 log10 -
IU/ml drop in HCV RNA by 12 weeks of treatment.
It should be acknowledged that a sizable proportion of
patients with a history of PegIFN/RBV treatment failure do not
have a precise record of their modality of non-response.
HCV genotype 1 patients who fail to achieve SVR with PegIFN/
RBV have a small likelihood of achieving an SVR when re-treated
with the same drugs at the same doses. The likelihood does not
exceed 10–15% for prior null responders and 30–40% for
response/relapsers. BOC and TVR are not licensed for genotypes
other than 1. Non-genotype 1 patients can thus be retreated with
PegIFN/RBV if they have an urgent indication for therapy and/or if
there is evidence of under-exposure to either pegylated IFN-a or
ribavirin during the ﬁrst course of therapy (due to dose adjust-
ments or poor adherence). Longer retreatment durations
(48 weeks for genotypes 2 and 3, 72 weeks for genotype 4
patients) can be considered, especially for patients with DVR in
the ﬁrst cycle of treatment.
Maintenance therapy with a low dose of pegylated IFN-a is not
recommended as it has shown no general efﬁcacy in preventing
chronic hepatitis C complications in the long-term. With the cur-
rent clinical development of a number of new drugs for the treat-
ment of chronic HCV infection, it is recommended that patients
who failed to respond to a ﬁrst course of PegIFN/RBV should be
included in clinical trials with these new drugs if possible.
Triple therapy for genotype 1 patients who experienced virological
failure during previous dual PegIFN/RBV therapy – results of phase III
studies with BOC and TVR
Phase II and III studies have now been conducted using BOC and
TVR in patients who have not achieved an SVR despite prior treat-
ment with dual antiviral therapy. The RESPOND-2 study, using
BOC, enrolled a total of 403 patients with previous relapse or par-
tial response [121]. Patients with previous null response were not
included in this study. All patients were treated with lead-in
treatment for 4 weeks with PegIFN/RBV. Patients were then ran-
domized to three groups. Group 1 received PegIFN/RBV for 44
additional weeks (total 48 weeks). Group 2 received response-
guided therapy, with all patients receiving PegIFN/RBV and BOC
for 32 additional weeks (up to week 36). Those patients in group
2 with undetectable HCV RNA at week 8 and 12 completed ther-
apy at week 36, whereas those patients who had detectable HCV
RNA at week 8 but were negative at week 12 continued PegIFN/
RBV alone from week 36 until week 48. Group 3 received PegIFN/
RBV and BOC for an additional 44 weeks. SVR rates were 21%,
59%, and 66% in groups 1, 2, and 3 respectively. Subgroup analy-
ses showed SVR rates in patients with previous relapse of 29%,
69%, and 75%, and in patients with previous partial response of
7%, 40%, and 52% in groups 1, 2, and 3 respectively.
In the REALIZE study, using TVR, 663 patients with previous
relapse, partial response or null response were randomized into
three groups [122]. The PR48 group (control) received PegIFN/
RBV for 48 weeks, the T12PR48 group received PegIFN/RBV for
48 weeks with TVR (i.e. triple therapy) for the ﬁrst 12 weeks,
and the lead-in T12PR48 group received the same as T12PR48
but preceded by 4 weeks lead-in with PegIFN/RBV. Overall SVR
rates were 17%, 64%, and 66% for the 3 groups respectively. Sub-
group analysis indicated SVR rates of 24%, 83%, and 88% for prior
relapsers, 15%, 59%, and 54% for prior partial responders, and 5%,
29%, and 33% for prior null responders.Journal of Hepatology 201In summary, there is a signiﬁcant beneﬁt in retreatment by PI-
containing triple therapy of patients who have previously had
virological failure with PegIFN/RBV therapy. The beneﬁts of triple
therapy over dual therapy are observed for patients with prior
relapse, partial response and null response patterns of failure.
The regimens used for BOC and TVR in the two studies are quite
different, but achieved similar SVR rates. BOC has not been used
extensively in patients with a prior null response. The PROVIDE
study of patients who were in the control arms of phase II or III
studies and who were classiﬁed there as null responders, and
were then re-treated with BOC triple therapy, showed an SVR
rate of 38%, with better results in those having a >1 log drop in
HCV RNA during the 4 week lead-in [123].
Cirrhotic patients had inferior outcomes in all treatment
groups and response-guided therapy is not licensed for cirrhotic
patients, irrespective of the prior treatment response to dual
therapy. For non-cirrhotic relapsers, response-guided therapy
can be used with either drug. Prior partial or null responders
require a full duration of therapy with either drug and
response-guided therapy should not be used.
The stopping rules for futility are identical to those applied in
treatment-naïve patients for both BOC and TVR. Treatment fail-
ure is strongly associated with the emergence of viral resistance.
The long term signiﬁcance of viral resistance is unknown but, in
patients with a low chance of response to PI-based triple therapy
(cirrhotic prior null responders), the balance of potential for cure
should be set against the on-going and rapid development of new
oral antivirals and the possibility that failed PI treatment may
have an impact on the effectiveness of future agents (by selection
of PI-resistant species).
Patients failing to respond to BOC should not be retreated
with TVR or vice versa.
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• In patients awaiting transplantation, antiviral therapy,
when feasible, prevents graft re-infection if an SVR is
achieved 
(recommendation B2)
• Antiviral therapy can be started while awaiting LT, with
the goal of achieving an SVR or at least serum HCV
RNA negativity before LT 
(recommendation C2)
• In patients with Child-Pugh B cirrhosis, antiviral therapy
is offered on an individual basis in experienced centres,
preferentially in patients with predictors of good 
response 
(recommendation C2)
• Patients with Child-Pugh C cirrhosis should not be
treated with the current IFN-α-based antiviral regimens,
due to a high risk of life-threatening complications 
(recommendation A1)
• Treatment can be started at low doses of pegylated
IFN-α and ribavirin, following a low accelerated dose
regimen, or at full doses. In the latter case, dose 
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Treatment of patients with severe liver disease
Compensated cirrhosis
Treatment is strongly recommended for patients with compen-
sated cirrhosis, in order to prevent the complications of chronic
HCV infection that occur exclusively in this group in the short to
mid-term. Indeed, large cohort studies and meta-analyses have
shown that an SVR in patients with advanced ﬁbrosis is associated
with a signiﬁcant decrease of the incidence of clinical decompen-
sation and HCC [124,125]. However, the SVR rates with PegIFN/
RBV are lower in patients with advanced ﬁbrosis or cirrhosis than
in patientswithmild tomoderate ﬁbrosis. Though superior to dual
therapy, SVR rates in response to PI-inclusive triple therapy of
genotype 1 patients are also negatively affected by ﬁbrosis stage.
Particular care should be taken inmonitoring andmanagement
of the side-effects of dual and triple therapy in this group of
patients, who are generally older and have a worse tolerance than
patientswith less advanced liver disease. Emergingdata emphasise
a signiﬁcant rate of side-effects and AEs during treatment of cir-
rhotic patients with PI-containing regimens, especially those with
a platelet count <100,000/mm3 and serum albumin levels <35 g/dl
at baseline [36]. For this reason PI-based triple therapy in patients
with compensated advanced liver disease should be managed in
reference centres. There is no role for current triple therapy in
patientswith decompensated liver disease. Due toportal hyperten-
sion and hypersplenism, leukocyte and platelet counts at baseline
may be low in cirrhotic patients. Hematological side effects are
more frequent in cirrhotic than in non-cirrhotic patients [126],
and may contraindicate therapy. Growth factors might be particu-
larly useful in this group. For instance, the thrombopoietin agonist
eltrombopag has been used to raise the platelet count in patients
with HCV cirrhosis, and higher platelet counts may enable admin-
istration of IFN-a [113]. Theremaybe a risk of portal vein thrombo-
sis, particularly if high platelet counts are achieved for patients
with advanced cirrhosis. Therefore, eltrombopag should be used
cautiously and simply to raise platelets to a low but safer level.
Irrespectiveof the achievementof anSVR, patientswith cirrhosis
should undergo regular surveillance for the occurrence of HCC and
for portal hypertension, as the risk of complications is decreased
but not abolished when HCV infection has been eradicated.
Recommendations
• Patients with compensated cirrhosis should be treated,
in the absence of contraindications, in order to prevent
short- to mid-term complications 
(recommendation B2)
• Monitoring and management of side-effects, especially
in patients with portal hypertension, low platelet count
and low serum albumin, should be done particularly
carefully. Growth factors may be useful in this group
(recommendation C2)
• Patients with cirrhosis should undergo regular 
surveillance for HCC, irrespective of SVR 
(recommendation A1)reductions and treatment interruptions are required in
more than 50% of cases 
(recommendation C2)Patients with an indication for liver transplantation
Liver transplantation (LT) is the treatment of choice for patients
with end-stage liver disease. However, hepatitis C recurrence
due to graft reinfection is universal after transplantation [127].408 Journal of Hepatology 201Antiviral therapy in patients awaiting transplantation prevents
graft reinfection if SVR is achieved [128–130]. More than half of
patients have contraindications to the use of PegIFN/RBV, and
the results of therapy are generally poor in this group of individ-
uals with liver disease in a very advanced phase. Antiviral ther-
apy is indicated in patients with conserved liver function
(Child-Pugh A) in whom the indication for transplantation is
HCC. In patients with Child-Pugh B cirrhosis, antiviral therapy
may be offered on an individual basis in experienced centres,
preferentially in patients with predictors of good response, such
as patients infected with HCV genotypes 2 or 3, or patients with
a low baseline HCV RNA level. Patients with Child-Pugh C cirrho-
sis should not be treated with IFN-a-based regimens, due to a
high risk of life-threatening complications [128–130].
In those individuals with severe liver disease who can be trea-
ted before transplantation, antiviral therapy should be started as
soon as possible,with the goal of achieving an SVR [130], or at least
to achieve serum HCV RNA negativity at the time of transplanta-
tion [128,129]. Treatment can be started at low doses of pegylated
IFN-a and ribavirin, following a low accelerated dose regimen, or
at full doses. In the latter case, dose reductions and treatment
interruptions are required in more than 50% of cases. Hematolog-
ical AEs (anemia, neutropenia, and thrombocytopenia) are partic-
ularly frequent in patients with end-stage liver disease because of
portal hypertension. Treatment therefore requires close monitor-
ing and dosemodiﬁcations. The use of growth factors (EPO and ﬁl-
grastim) might be helpful to control hematological side effects.
There are no published data to describe the use of PI-based regi-
mens in the treatment of waiting list patients with very advanced
liver disease. Both TVR and BOC exhibit hematologic toxicity and
an increased risk of severe infections, so the side-effect proﬁle in
this patient group may be particularly challenging.
Recommendations4 vol. 60 j 392–420
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Post-liver transplantation recurrence
HCV infection recurrence is universal in patients with detectable
HCV RNA at the time of liver transplantation [127]. The course of
HCV-related liver disease is accelerated in LT recipients and
approximately one third of them develop cirrhosis within 5 years
following transplantation [131,132]. Successful therapy has been
shown to have a positive impact on both graft and patient sur-
vival [133].
Patients with post-transplant recurrence of HCV infection
should be considered for therapy once chronic hepatitis is estab-
lished and histologically proven. These patients generally have a
better background for therapy than at the acute stage of re-infec-
tion and related hepatitis, i.e. less immunosuppression, an
improved clinical status that ensures better tolerability, and a
lower risk of triggering graft rejection upon IFN-a-based therapy.
The presence of signiﬁcant ﬁbrosis or portal hypertension one
year after transplantation is predictive of rapid disease progres-
sion and graft loss, and urgently indicates antiviral treatment
[134,135]. In patients with less advanced disease, such as those
with ﬁbrosis restricted to the portal tract and no portal hyperten-
sion, the indication of therapy must be weighted to the likelihood
of a sustained viral eradication and to the risk of antiviral treat-
ment-associated complications. Nevertheless, patients with less
severe graft ﬁbrosis have a better chance of an SVR than those
with more advanced disease.
Published efﬁcacy data are limited to the experience with Peg-
IFN/RBV dual therapy, though preliminary reports of PI-based tri-
ple therapy for post-transplant patients are emerging. With dual
therapy, the likelihood of an SVR in the post-transplant setting is
in the order of 30% overall, with better response rates in patients
infected with HCV genotype 2 or 3 than genotype 1 [136–138]. As
renal dysfunction is common in LT recipients, ribavirin doses
need to be adjusted accordingly. The relatively low efﬁcacy of
PegIFN/RBV therapy in HCV-infected transplant recipients is at
least partly due to the high incidence of side effects that demand
frequent dose adjustments and treatment interruptions. Anemia
is the most common cause of treatment interruption in this set-
ting (10–40% of the patients) [136,137]. Therefore, the use of EPO
has been recommended, but without supporting evidence to
show that SVR rates are enhanced. Liver dysfunction may be
observed during IFN-a therapy, and graft rejection is an impor-
tant cause of this [139]. Whenever liver tests deteriorate signiﬁ-
cantly during the course of antiviral therapy, a liver biopsy should
be performed to diagnose the cause and to guide treatment deci-
sions. There is no evidence for a beneﬁt of low-dose pegylated
IFN-a maintenance therapy in patients who do not achieve an
SVR with dual therapy.
Drug-drug interactions are particularly important in the post-
transplant setting. IFN-a and ribavirin are relatively free of signif-
icant interactions. The PIs, TVR and BOC, are potent inhibitors of
hepatic cytochrome P450 3A4 (CYP3A4), the main enzyme
responsible for tacrolimus and cyclosporin metabolism. Co-
administration of these drugs with a PI causes a dramatic
increase in exposure to the tacrolimus or cyclosporin [140,141].
Thus, commencement of a PI-containing regimen requires an
immediate and profound reduction of cyclosporin or tacrolimus
dose. In addition, cessation of the PI requires an immediate resto-
ration of pre-treatment immunosuppressive dose. Emerging, but
as yet unpublished experience conﬁrms that PI-based treatmentJournal of Hepatology 201can be delivered with caution in the post-transplant setting
[142].
Recommendations
• Patients with post-transplant recurrence of HCV 
infection should be considered for therapy once chronic
hepatitis is established and histologically proven 
(recommendation B2). Significant fibrosis or portal
hypertension one year after transplantation predict rapid
disease progression and graft loss, and indicate more
urgent antiviral treatment 
(recommendation B2)
• For patients with HCV genotype 1 infection, PI-based
triple therapy can be used, but frequent monitoring
and dose adjustment of tacrolimus and cyclosporin are
required 
(recommendation B1)
• Graft rejection is rare but may occur during IFN-α 
treatment (recommendation C2). A liver biopsy should
be performed whenever liver tests worsen on antiviral
therapy 
(recommendation C2)Treatment of special groups
HIV co-infection
Progression of liver disease is accelerated in patients with HIV-
HCV co-infection, in particular for those with a low CD4-positive
cell count and impaired immune function. For this reason, early
antiretroviral therapy should be considered in patients with
HIV-HCV co-infection [143]. If the patient has severe immunode-
ﬁciency, with a CD4-positive cell count <200 cells/ll, the CD4
count should be improved using highly active antiretroviral ther-
apy prior to commencing anti-HCV treatment. During PegIFN/
RBV treatment, didanosine, stavudine, and zidovudine should
be avoided. The role of abacavir is debated and recently published
data do not contraindicate its use with ribavirin [144]. Liver dis-
ease severity should be assessed prior to therapy by means of a
liver biopsy or by non-invasive assessment (serological tests or
LSM).
Indications for HCV treatment are identical to those in
patients with HCV mono-infection [145]. The same pegylated
IFN-a regimen should be used in HIV-co-infected patients as in
patients without HIV infection. For patients receiving dual ther-
apy with PegIFN/RBV, published data do not clearly deﬁne the
preferred dose of ribavirin and the optimal duration of treatment.
For genotypes 2 and 3, ﬁxed dose 800 mg/day of ribavirin can be
recommended. For HCV genotype 1 patients, the total treatment
exposure to ribavirin is associated with the likelihood of achiev-
ing SVR [146]. However, the efﬁcacy of weight-based (1 to 1.2 g/
day) ribavirin is not clearly superior to ﬁxed dose (800 mg/day)
treatment [147]. The higher dose is associated with greater
hemoglobin reduction. For easy-to-treat HCV genotypes, a ran-
domized comparison of 48 vs. 24 weeks of treatment has not4 vol. 60 j 392–420 409
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been made. Monitoring of viral kinetics on treatment should be
performed and the patients should be treated according to their
virological responses at weeks 4 and 12. For patients with favour-
able genotypes who achieve serum HCV RNA negativity at
4 weeks (RVR), a 24 week duration of therapy may be sufﬁcient.
For those who achieve an EVR, but not an RVR, 48 weeks duration
is recommended regardless of HCV genotype. For a given geno-
type treated with PegIFN/RBV dual therapy, rates of SVR are gen-
erally lower for co-infected than for HCV mono-infected patients.
HIV-positive patients who are infected with HCV genotype 1,
whether HCV treatment-naïve or treatment-experienced, should
be considered for HCV antiviral triple therapy with pegylated
IFN-a, ribavirin, and TVR or BOC. Recently presented data show
that these combinations can be used safely with selected con-
comitantly-given HIV antiviral regimens, and that SVR rates are
enhanced by the inclusion of the HCV PI [148,149]. In those stud-
ies, permitted HIV antivirals included nucleoside analogues,
efavirenz, raltegravir and selected ritonavir-boosted HIV protease
inhibitors. Emerging data will clarify the clinically relevant drug-
drug interactions between TVR, BOC and the established HIV
antivirals. Collaborative management including the hepatologist,
the HIV physician, and the pharmacist, and awareness of known
and potential drug-drug interactions, will be the key to safe and
successful use of these and future HCV DAAs in HIV-positive
patients [150].
Consensus guidelines for the management of acute HCV in
HIV-infected individuals were published in 2011 [151]. Regard-
less of infecting genotype, the guideline recommended the com-
bination of pegylated IFN-a and weight-based ribavirin for
treatment. Duration of treatment can be determined by kinetics
of response, with 24 weeks of treatment given to those with
serum RNA negativity at 4 weeks (RVR), and 48 weeks for those
with ﬁrst serum RNA negativity delayed beyond 4 weeks.
Recommendations
• Indications for HCV treatment in HCV/HIV co-infected
persons are identical to those in patients with HCV
mono-infection 
(recommendation B2)
• The same pegylated IFN-α regimen can be used in HIV-
co-infected patients as in patients without HIV infection,
though prolongation of treatment can be considered for
patients with genotypes 2 and 3 who exhibit slow early
viral kinetics
(recommendation B2)
• HIV patients who are co-infected with HCV genotype
1 should be considered for TVR-containing or BOC-
containing triple therapy, but special care should 
be taken to minimise or avoid potential drug-drug 
interactions 
(recommendation B1)
• HIV patients with a diagnosis of acute HCV infection
should be treated with PegIFN/RBV, with duration 
dependent on viral kinetics independent of HCV 
genotype 
(recommendation B2)410 Journal of Hepatology 201HBV co-infection
In patients with HCV-HBV co-infection, the HBV DNA level is
often low or undetectable, although it may ﬂuctuate widely,
and HCV is usually the main driver of chronic hepatitis activity.
Patients should be carefully characterized for the replicative sta-
tus of both HBV and HCV, and hepatitis delta virus infection
should be sought. When HCV is replicating and causes liver dis-
ease, it should be treated with PegIFN/RBV following the same
rules as applied to mono-infected patients. The SVR rates in this
group are broadly comparable to those in HCV mono-infected
patients, or even higher [152]. There is a potential risk of HBV
reactivation during or after HCV clearance [153]. In that case, or
if HBV replication is detectable at a signiﬁcant level, concurrent
HBV nucleoside/nucleotide analogue therapy may be indicated,
though there may be drug interactions with PIs. There is no infor-
mation on the use of PI-based triple therapy in this population of
patients, though HCV PIs should be used for treatment of patients
who are co-infected by HBV and HCV genotype 1.
Recommendations
• Patients should be treated with pegylated IFN-α, 
ribavirin, and PIs following the same rules as mono-
infected patients 
(recommendation B2)
• If HBV replicates at significant levels before, during
or after HCV clearance, concurrent HBV nucleoside/
nucleotide analogue therapy may be indicated 
(recommendation C2)
Treatment of patients with co-morbidities
Hemodialysis patients. HCV infection is prevalent in the hemodi-
alysis population and is associated with an increased risk for all-
cause and liver-related mortality. Cardiovascular disease
remains, however, the main cause of death in dialysis patients
irrespective of HCV status. As in all settings, the candidacy of a
dialysis patient for antiviral therapy requires special consider-
ation of co-morbid conditions, since the liver disease may have
little impact on predicted morbidity and mortality of that patient.
HCV-associated liver damage may be accelerated by immunosup-
pression, and IFN-a may precipitate renal graft rejection. For
these reasons, antiviral therapy should be considered for all
hemodialysis patients who will be candidates for renal transplan-
tation. Reﬂecting concerns about the use of ribavirin in this set-
ting, most published data describe the use of IFN-a
monotherapy, mostly in small studies using conventional IFN-a
[154]. Pegylated IFN-a can be used and may be associated with
improved SVR rates [155,156]. Pegylated IFN-a accumulates in
patients with advanced renal dysfunction, so dose reduction is
required. The recommended dose of PEG IFN-a 2a in this setting
is 135 lg/week. Combination treatment with PegIFN/RBV can be
considered by experienced physicians, and may enhance SVR
rates [157]. Individualized ribavirin dosing of 200 mg/day or
200 mg/every other day or 200 mg thrice weekly after
hemodialysis, and substantial hematopoietic support is essential.
Pharmacokinetic studies in patients with end-stage renal disease
reveal no signiﬁcant impact of renal dysfunction on drug expo-4 vol. 60 j 392–420
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sure, suggesting that both TVR and BOC might be used to treat
HCV infection in this setting [158,159]. There are no published
data to describe the safety and efﬁcacy of PI-inclusive antiviral
treatment of renal failure patients with HCV, so clinical studies
in this population are essential. A recently presented study that
included 36 treatment-naïve genotype 1 hemodialysis patients
showed that TVR-containing triple therapy had superior efﬁcacy
than PegIFN/RBV dual therapy, but triple therapy was associated
with more anemia [160].
Recommendations
• Hemodialysis patients, particularly those who are 
suitable candidates for renal transplantation, should be
considered for antiviral therapy 
(recommendation A2)
• Antiviral treatment should comprise pegylated IFN-α at
an appropriately reduced dose 
(recommendation A1)
• Ribavirin can be used at very low doses, but with 
caution 
(recommendation B2)
• BOC and TVR can be used with caution in patients with
impaired creatinine clearance, and dose adjustment is
probably unnecessary 
(recommendation C1)Non-hepatic solid organ transplant recipients. HCV infection in kid-
ney transplant recipientsmay be associatedwith an increased rate
of liver ﬁbrosis progression. Most studies of kidney transplant
cohorts show that HCV positivity is associatedwith impaired renal
graft and patient survival. Impaired graft survival partly reﬂects
increased patient mortality. In addition, speciﬁc HCV-related
causes such as glomerulonephritis and increased risk of diabetes
will affect graft outcome. HCV-positivity is associated with
increased all-cause and liver-related mortality, though cardiovas-
cular disease remains themain cause of patient death [161]. As cir-
rhosis is an important predictor of poor post-transplant survival
after kidney transplantation, it is advisable tomake an assessment
of liver ﬁbrosis stage in all HCV-positive kidney transplant candi-
dates [162]. For patients with established cirrhosis who fail (or
are unsuitable for) HCV antiviral treatment, isolated renal trans-
plantation may be contraindicated and consideration should be
given to combined liver and kidney transplantation [163].
Treatment of chronic HCV infection with PegIFN/RBV in kid-
ney transplant recipients is associated with a risk of acute or
chronic cellular rejection of 30% or more, resulting in graft loss
and reduced patient survival. Therefore, PegIFN/RBV therapy
has additional risks in these patients, and the decision to give
antiviral therapy must consider these risks. Where possible,
patients with an indication for kidney transplantation should be
treated for hepatitis C prior to transplantation [164].Journal of Hepatology 201Data on HCV infection after heart transplantation are scarce
and controversial, with studies showing unaltered or decreased
survival rates in patients infected with HCV. No studies on the
risks and beneﬁts of antiviral therapy are available in these
patients and the risk of graft rejection on IFN-a treatment
remains unclear. In this context, treatment of chronic HCV infec-
tion in heart transplant recipients cannot be recommended and
the indication should be assessed on a case-by-case basis, if
HCV infection is life-threatening.
International guidelines list chronic HCV infection as a contra-
indication to lung transplantation [165]. Treatment of lung trans-
plant candidates before transplantation has been recommended
by some authors, but there is limited experience with this
approach. No data are available on the impact of HCV infection
and its treatment after pancreas or small bowel transplantation.Recommendations
• HCV treatment before kidney transplantation may avoid
liver-related mortality in the post-transplant patient,
and may prevent HCV-specific causes of renal graft
dysfunction. Where possible, antiviral therapy should be
given to potential transplant recipients before listing for
renal transplantation 
(recommendation B1)
• IFN-α-based antiviral treatment is associated with a
significant risk of renal graft rejection, and it should
be avoided unless there is a powerful indication for
antiviral treatment, e.g. aggressive cholestatic hepatitis
(recommendation A1)
Active drug addicts and patients on stable maintenance substitution.
Ageing cohorts of PWID with chronic HCV and low treatment
uptake are making a signiﬁcant contribution to the population
with advanced liver disease and to liver-related mortality
[166,167]. In several countries where PWID are the major popu-
lation affected by HCV, 20–25% of deaths among HCV-infected
individuals are from liver disease and 15–30% are from drug-
related causes [17]. The prevalence of HCV among PWID is
65% [168–170] and >80% among long-term PWID [169]. HCV
genotypes 1a, 1b, and 3a are common among PWID [171], while
4d is common among PWID in Europe [172,173], and 6 is com-
mon in Southeast Asia [7]. The incidence of HCV in PWID is 5–
45% per annum [174,175]. Factors associated with HCV among
PWID include female gender [176], ethnicity [177], unstable
housing [178], frequent injecting cocaine use [176,179], impris-
onment [180], injecting networks [181] and borrowing injecting
equipment [179]. High coverage of combined harm-reduction
programs (e.g. opiate substitution treatment [OST] and needle
exchange programs) can reduce HCV incidence [182,218].
Despite misconceptions among affected populations and
health care workers, no liver toxicity is reported for heroin
[183] or methadone [184]. Buprenorphine occasionally increases
transaminases [185]. Methylenedioxymetamphetamine (MDMA)4 vol. 60 j 392–420 411
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rarely causes acute liver failure due to direct liver toxicity [186]
and little is known about methamphetamine-related liver toxic-
ity [187]. Daily cannabis use may be associated with more
advanced liver ﬁbrosis, after adjustment for alcohol and age
[188], and with liver steatosis [189]. Heavy alcohol consumption
is associated with a higher risk of cirrhosis [190]. Tobacco smok-
ing may increase inﬂammation and ﬁbrosis progression [19], but
further studies are needed [218].
HCV treatment can be considered for PWID, provided they
wish to receive treatment and are able and willing to main-
tain regular appointments. Guidelines for pre-therapeutic
assessment for HCV-infected individuals are available [17,24].
Modelling studies suggest that implementation of HCV treat-
ment for PWID could reduce transmission [9,191]. A history
of IDU and recent drug use at treatment initiation are not
associated with reduced SVR and decisions to treat must be
made on a case-by-case basis. PWID with ongoing social issues
and/or with a history of psychiatric disease or with more fre-
quent drug-use during therapy are at risk of lower adherence
and reduced likelihood of achieving SVR and need to be mon-
itored closely during therapy, and also need more supporting
measures. Factors independently associated with impaired
adherence and failure of treatment completion among drugs
users include lower levels of education and unstable housing
[84]. Factors independently associated with lower SVR among
drug users include poor social functioning [192], a history of
untreated depression [193] and ongoing frequent drug use
during treatment [193,218].
HCV-infected PWID often have complex social, medical and
psychiatric comorbidities, complicating decisions around care
[194]. Poor knowledge and inaccurate perceptions about HCV
are barriers for accessing HCV care [195,196]. Factors associ-
ated with not receiving HCV treatment include older age
[197], minority ethnicity [197], ongoing or former drug use
[194,198–200], ongoing alcohol use [197,198], advanced liver
disease [199], co-morbid medical disease [197,200], psychiatric
disease [197,199] and opioid substitution therapy (OST)
[194,198]. A number of these factors are relevant to PWID
[218].
HCV treatment has been delivered successfully to drug users
through various clinical models, including within general hospi-
tal liver disease and viral hepatitis clinics, drug detoxiﬁcation
clinics, OST clinics, prisons, and community-based clinics. Strate-
gies to enhance treatment adherence were discussed in section
‘Treatment adherence’ [218].
In general, studies ﬁnd that a history of IDU does not com-
promise adherence [84,85], treatment completion [84,201] or
SVR. Indeed, recent drug use at treatment initiation has lim-
ited impact on adherence [84,85], treatment completion
[202–204], or SVR [192,203–206]. However, one study has
reported lower treatment completion in those with recent
drug use at treatment initiation [202]. Occasional drug use
during treatment does not seem to impact adherence [84],
treatment completion [84,204], or SVR [204,206]. However,
lower adherence [84,85] and SVR [94,207] has been observed412 Journal of Hepatology 201in persons with frequent drug use (daily/every other day) dur-
ing treatment. When discontinuation occurs, it often occurs
early during therapy [208]. In adherent patients, alcohol use
has no negative impact on SVR [102]. HCV treatment does
not have an impact on drug dependency treatment or increase
drug use [206,218].
DAA clinical development programs have excluded individ-
uals with active drug use, but many trials have included those
on OST. DAA-based safety and treatment outcome data has not
been presented on clinical trial sub-populations of individuals
on OST. Drug-drug interaction studies have been undertaken
with TVR and methadone [209] and buprenorphine [210], with
no clinically important interactions observed. Interaction stud-
ies have also been undertaken for BOC with methadone and
buprenorphine, and clinically signiﬁcant changes in exposure
to the methadone and buprenorphine were not observed
[211,212,218].
In addition to OST, antidepressants, antipsychotics and seda-
tives are frequently used in patients or used by patients with
addiction problems. Escitalopram and most probably citalopram
can be used with both HCV PIs. Zolpidem can be considered safe.
Because of CYP3A4 inhibition by the PIs, midazolam and alpraz-
olam should not be coadministered with BOC and TVR. Pimozid
should not be coadministered with BOC and TVR. CYP3A4 is also
involved in the metabolism of sertraline and mirtazepine. In con-
trast, olanzapine can be considered without signiﬁcant interac-
tion. Fluoxetine and paroxetine appear safe with BOC and TVR
[213–216,218].
Of course, pharmacokinetic studies on recreational and illicit
drug use have not been performed. However the practical impor-
tance in patients with a background of drug use is evident. Her-
oin, as a 3,6-diacetyl derivative of morphine, is ﬁnally
metabolized mainly by CYP3A4. Because of this, an increase of
heroin levels is possible when BOC or TVR is used. Unfortunately
no pharmacokinetic data are available. For tetrahydrocannabinol
(THC) a profound interaction is not likely. The concomitant use of
amphetamine (MDMA) and ecstasy (PMA, PMMA) should be
avoided. The consequences of overdosing can be fatal due to
hyperthermia, cardiac arrhythmia or liver failure. Because of
the complexity of the metabolism of cocaine the effect of a con-
comitant use with BOC or TVR is difﬁcult to predict and should be
avoided. The same applies to crack cocaine use. Interactions of
barbiturates and benzodiazepines with TVR and BOC may
increase the levels of barbiturates and benzodiazepines (resulting
in potentially life-threatening midazolam overdose), and also
reduce the levels of TVR and BOC, thus affecting antiviral efﬁcacy.
In summary, illicit drug use should be avoided during antiviral
treatment with TVR and BOC [217–219].
The proportion of patients with a history of IDU undergoing
liver transplantation for HCV-related cirrhosis or HCC is 5–10%
[220,221]. Relapse to drug use following transplantation is rare
[220,221]. Selection criteria for liver transplantation include: 6–
24 months of drug abstinence, controlled psychiatric disease
and the presence of stable social support networks [221,222].
OST is not a contraindication [218,220,222–228].4 vol. 60 j 392–420
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Recommendations
• PWID should be routinely and voluntarily tested for HCV antib
(recommendation B1)
• PWID should be provided with clean drug injecting equipment 
reduction programs, including in prisons 
(recommendation B1)
• Pre-therapeutic education should include discussions of HCV 
risk, and harm reduction strategies 
(recommendation B1)
• PWID should be counselled to moderate alcohol intake, or to a
(recommendation A1)
• PWID should be counseled to moderate cannabis use, or to ab
(recommendation B2)
 
• HCV treatment for PWID should be considered on an individua
(recommendation A1)
• Pre-therapeutic assessment should include an evaluation of h
finances, nutrition, and drug and alcohol use. PWID should be
(recommendation A1)
 
• A history of IDU and recent drug use at treatment initiation are
made on a case-by-case basis 
(recommendation B1)
• Drug and alcohol users or any other patients with on-going soc
more frequent drug use during therapy, are at risk of lower adh
monitored more closely during therapy and need more intensiv
(recommendation B1)
• Evaluation of safety and efficacy of TVR and BOC in PWID is 
(recommendation C1)
 
• TVR and BOC can be used in PWID on OST (recommendatio
methadone and buprenorphine dose adjustment, but monitorin
(recommendation B1)
• Consideration of TVR and BOC use in PWID should be undert
be advised to await further data and/or potential development 
(recommendation B1)
• Awareness should be raised that LT is a therapeutic option in t
(recommendation B2)
  
• OST is not a contraindication for liver transplantation and indiv
(recommendation A1)Hemoglobinopathies. The most frequent hemoglobinopathy asso-
ciated with chronic hepatitis C is thalassemia major, which
requires frequent blood transfusions and is prevalent in countries
where blood supply screening may be, or has been, suboptimal. In
the few published clinical trials, these patients had a higher inci-
dence of anemia during PegIFN/RBV therapy. Therefore, they can
be treated with standard combination therapy, but these compli-
cations should be carefully managed with growth factors and
blood transfusions when needed [229].Journal of Hepatology 201Chronic HCV infection is also frequent in individuals with
sickle cell anemia. No trials with antiviral therapy have been pub-
lished in this population. Individual cases have been successfully
treated with PegIFN/RBV. In the absence of published studies to
examine the safety of BOC and TVR in the treatment of patients
with hemoglobinopathies, there is no reason to consider that
these drugs are speciﬁcally contraindicated. Both are associated
with anemia when used with PegIFN/RBV, so blood transfusion
may be needed.4 vol. 60 j 392–420 413
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Follow-up of untreated patients and of patients with treatment
failure
Untreated patients with chronic hepatitis C and those who failed
to respond to previous treatment should be regularly followed.
The reason(s) for non-treatment and treatment failure should
be clearly documented. For patients who have failed prior treat-
ment with PegIFN/RBV or PI-based triple therapy, the pattern of
virological response and failure should be carefully documented.
Review should include an assessment of patient suitability for
clinical trials of investigational DAAs, and suitability for retreat-
ment with newly licensed drugs, when available. Previous guide-
lines recommended performing a liver biopsy every 3 to 5 years.
With non-invasive methods, more frequent screening can be per-
formed. Thus, untreated patients should be assessed every 1 to
2 years with a non-invasive method. Patients with cirrhosis
should undergo speciﬁc screening for HCC every 6 months.
Recommendations
• Untreated patients with chronic hepatitis C and those
who failed prior treatment should be regularly followed
(recommendation C2)
• Non-invasive methods for staging fibrosis are 
best suited for follow-up assessment at intervals 
(recommendation C2)
• HCC screening must be continued indefinitely in 
patients with cirrhosis 
(recommendation A2)Treatment of acute hepatitis C
Most patients with acute hepatitis C are asymptomatic, but a
high rate of chronicity is expected (50–90%). Symptomatic dis-
ease, female gender, a young age, and genetic polymorphisms
in the region upstream of the IL28B gene have been associated
with spontaneous viral clearance, but none of these parameters
accurately predicts spontaneous resolution at the individual
level.
Patients with acute hepatitis C should be considered for
antiviral therapy in order to prevent progression to chronic hep-
atitis C. High SVR rates (>90%) have been reported with pegylated
IFN-a monotherapy, essentially in series of symptomatic
patients, regardless of the HCV genotype. Combination therapy
with ribavirin does not increase the SVR rate in this setting, but
may be considered during treatment in patients with slow
response and other negative predictors of treatment response
[230–236]. No data are available on the use of triple therapy in
this group.
The ideal time point for starting therapy has not been ﬁrmly
established. Some investigators estimate that the onset of ALT
elevation, with or without clinical symptoms, may be the ideal
time point for treatment [237–240]. It has also been suggested
that patients should be followed with 4-weekly HCV RNA quan-
tiﬁcation and that only those who remain HCV positive at
12 weeks from onset should be treated [241]. The treatment of414 Journal of Hepatology 201acute hepatitis C should be based on pegylated IFN-a mono-
therapy, i.e. pegylated IFN-a2a, 180 lg/week, or pegylated IFN-
a2b, 1.5 lg/kg/week, for 24 weeks. Patients who fail to achieve
an SVR with this regimen may be retreated for 48 weeks, with
or without ribavirin at the usual doses. For those with genotype
1 infection who fail to respond to IFN-a monotherapy, PI-based
triple therapy including TVR or BOC could also be considered.
There is currently no indication for administering IFN-a as
post-exposure prophylaxis in the absence of documented HCV
transmission.
Recommendations
• Pegylated IFN-α monotherapy (pegylated IFN-α2a,
180 μg/week or pegylated IFN-α2b, 1.5 μg/kg/week,
for 24 weeks) is recommended in patients with acute
hepatitis C, and achieves SVR in as many as 90% of
treated patients 
(recommendation B2)
• Patients failing to respond to monotherapy should be
re-treated with PegIFN/RBV or PI-based triple therapy
(recommendation C2)Perspective of new and emerging treatments
The protease inhibitors, TVR and BOC, have changed but not
transformed the management of chronic HCV infection. They
are licensed only for genotype 1 infection, and the outcome of tri-
ple therapy remains dependent on the use of IFN and on the sen-
sitivity of the patient and the virus to treatment with IFN and
ribavirin. Thus, the largest impact has been on treatment of pre-
viously untreated HCV genotype 1 patients and on treatment of
those HCV genotype 1 patients who relapsed after prior treat-
ment with PegIFN/RBV. Side-effects of triple therapy are signiﬁ-
cant, particularly in patients with cirrhosis. Response rates to
triple therapy for patients with prior partial and null response
to PegIFN/RBV remain disappointing, particularly for those with
cirrhosis, and despite longer duration of therapy.
Meanwhile, we are feasting on the results of trials of DAA
drugs and combinations, including IFN-free regimens [25]. SVR
rates in excess of 90% for treatment duration of 12 weeks have
been reported. Most studies continue to focus on genotype 1
infection, and most exclude cirrhosis. Nevertheless, doctors and
patients share optimism that emerging antivirals will treat all
genotypes, with cure for the majority and with few side-effects
in short duration therapy. Reﬂecting that optimism, many doc-
tors and patients with all HCV genotypes are choosing to defer,
rather than to proceed with dual or triple therapy. An assessment
of liver disease stage is probably the main factor that inﬂuences
that choice. However, the threshold for deferral vs. immediate
treatment varies between experts, and is probably shifting in
response to the most recent trial results. As a consequence of
the shortcomings of dual and triple therapy, and reﬂecting our
optimism about drugs in development, our clinics are swelling
with patients who have high but realistic expectations that they
will be cured by a painless antiviral regimen, and in the
not-too-distant future. Where possible, patients should be4 vol. 60 j 392–420
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encouraged to participate in clinical trials, which are essential for
the timely development and licensing of new antiviral drugs and
regimens.
It seems likely that there will be a steady ﬂow of drugs to the
market. However, many of these drugs will have had little expo-
sure to the difﬁcult-to-treat groups with cirrhosis, liver failure,
renal failure, or HIV co-infection and other forms of immunosup-
pression. Nor are they likely to have been much exposed to
patients with other co-morbidities that demand treatment with
a range of drugs that will interact in a variety of ways with the
emerging antivirals. We need to be cautious in raising the expec-
tations of these difﬁcult-to-treat patients. We also need to focus
on the likely future problems of service provision, an issue not
addressed to a signiﬁcant extent by these guidelines. The accu-
mulation of difﬁcult patients, combined with the ‘‘warehousing’’
of the relatively easy-to-treat patients, followed by the marketing
and availability of a range of DAA regimens, will create an enor-
mous practical and logistic challenge. Physicians need to acquire
the appropriate expertise, develop an appropriate service for
delivery and guarantee adequate and proportionate funding to
manage the cohort. Failure to deliver on any of these aspects will
limit the enormous capacity that recent and on-going develop-
ments in drug development have the potential to deliver.
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